0001114483 false 2026 Q1 12/31 P2D 0.0114681 0.0066243 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure itgr:day itgr:installment iso4217:USD iso4217:MXN iso4217:USD iso4217:MYR iso4217:USD iso4217:UYU iso4217:USD iso4217:EUR iso4217:EUR itgr:segment 0001114483 2026-01-01 2026-04-03 0001114483 2026-04-24 0001114483 2026-04-03 0001114483 2025-12-31 0001114483 2025-01-01 2025-03-28 0001114483 2024-12-31 0001114483 2025-03-28 0001114483 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001114483 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001114483 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-04-03 0001114483 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-28 0001114483 us-gaap:AdditionalPaidInCapitalMember 2026-04-03 0001114483 us-gaap:AdditionalPaidInCapitalMember 2025-03-28 0001114483 us-gaap:TreasuryStockCommonMember 2025-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2024-12-31 0001114483 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-04-03 0001114483 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-28 0001114483 us-gaap:TreasuryStockCommonMember 2026-04-03 0001114483 us-gaap:TreasuryStockCommonMember 2025-03-28 0001114483 us-gaap:RetainedEarningsMember 2025-12-31 0001114483 us-gaap:RetainedEarningsMember 2024-12-31 0001114483 us-gaap:RetainedEarningsMember 2026-01-01 2026-04-03 0001114483 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-28 0001114483 us-gaap:RetainedEarningsMember 2026-04-03 0001114483 us-gaap:RetainedEarningsMember 2025-03-28 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-04-03 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-28 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-03 0001114483 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-28 0001114483 itgr:PrecisionCoatingLLCMember 2025-01-07 2025-01-07 0001114483 itgr:PrecisionCoatingLLCMember 2025-01-07 0001114483 itgr:VSiParyleneInc.Member 2025-02-28 2025-02-28 0001114483 itgr:VSiParyleneInc.Member 2025-02-28 0001114483 itgr:BiocoatIncorporatedMember 2025-12-04 2025-12-04 0001114483 itgr:BiocoatIncorporatedMember 2025-12-04 0001114483 itgr:AcquisitionsTwoThousandTwentyFiveMember 2026-04-03 0001114483 itgr:PrecisionCoatingLLCMember us-gaap:CustomerRelationshipsMember 2025-01-07 0001114483 itgr:VSiParyleneInc.Member us-gaap:CustomerRelationshipsMember 2025-02-28 0001114483 itgr:BiocoatIncorporatedMember us-gaap:CustomerRelationshipsMember 2025-12-04 0001114483 itgr:AcquisitionsTwoThousandTwentyFiveMember us-gaap:CustomerRelationshipsMember 2026-04-03 0001114483 itgr:PrecisionCoatingLLCMember us-gaap:TechnologyBasedIntangibleAssetsMember 2025-01-07 0001114483 itgr:VSiParyleneInc.Member us-gaap:TechnologyBasedIntangibleAssetsMember 2025-02-28 0001114483 itgr:BiocoatIncorporatedMember us-gaap:TechnologyBasedIntangibleAssetsMember 2025-12-04 0001114483 itgr:AcquisitionsTwoThousandTwentyFiveMember us-gaap:TechnologyBasedIntangibleAssetsMember 2026-04-03 0001114483 itgr:LongTermTechnologyAndPatentsMember 2026-04-03 0001114483 us-gaap:CustomerListsMember 2026-04-03 0001114483 itgr:CurrentTechnologyAndPatentsMember 2026-04-03 0001114483 us-gaap:TrademarksAndTradeNamesMember 2026-04-03 0001114483 itgr:LongTermTechnologyAndPatentsMember 2025-12-31 0001114483 us-gaap:CustomerListsMember 2025-12-31 0001114483 itgr:CurrentTechnologyAndPatentsMember 2025-12-31 0001114483 us-gaap:TrademarksAndTradeNamesMember 2025-12-31 0001114483 us-gaap:CostOfSalesMember 2026-01-01 2026-04-03 0001114483 us-gaap:CostOfSalesMember 2025-01-01 2025-03-28 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2026-01-01 2026-04-03 0001114483 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-28 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2026-04-03 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2025-12-31 0001114483 itgr:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2026-04-03 0001114483 itgr:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2025-12-31 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2026-04-03 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-12-31 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2026-04-03 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-12-31 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2023-02-28 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-03-31 0001114483 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2026-01-01 2026-04-03 0001114483 itgr:TermLoanATLAFacilityMember us-gaap:SecuredDebtMember 2026-01-01 2026-04-03 0001114483 us-gaap:LetterOfCreditMember itgr:TermLoanATLAFacilityMember us-gaap:LineOfCreditMember 2026-04-03 0001114483 us-gaap:StandbyLettersOfCreditMember itgr:TermLoanATLAFacilityMember us-gaap:LineOfCreditMember 2026-04-03 0001114483 us-gaap:StandbyLettersOfCreditMember 2026-04-03 0001114483 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember us-gaap:LineOfCreditMember 2026-01-01 2026-04-03 0001114483 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember us-gaap:LineOfCreditMember 2026-01-01 2026-04-03 0001114483 us-gaap:RevolvingCreditFacilityMember itgr:A2021CreditAgreementMember us-gaap:BridgeLoanMember 2026-03-25 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-03-18 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-03-18 0001114483 us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsOneMember 2025-03-18 2025-03-18 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsOneMember 2025-03-18 2025-03-18 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsOneMember 2025-03-18 2025-03-18 0001114483 us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsTwoMember 2025-03-18 2025-03-18 0001114483 us-gaap:ConvertibleDebtMember 2025-03-18 2025-03-18 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsThreeMember 2025-03-18 2025-03-18 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsThreeMember 2025-03-18 2025-03-18 0001114483 us-gaap:ConvertibleDebtMember itgr:DebtConversionTermsThreeMember 2025-03-18 2025-03-18 0001114483 itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-03-18 2025-03-18 0001114483 itgr:CappedCallOptionsMember itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-03-18 0001114483 us-gaap:FairValueInputsLevel2Member itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2026-04-03 0001114483 us-gaap:FairValueInputsLevel2Member itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2026-04-03 0001114483 us-gaap:FairValueInputsLevel2Member itgr:A2028ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-12-31 0001114483 us-gaap:FairValueInputsLevel2Member itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-12-31 0001114483 itgr:A2028ConvertibleSeniorNotesMember itgr:CappedCallOptionsMember 2026-04-03 0001114483 itgr:A2028ConvertibleSeniorNotesMember itgr:CappedCallOptionsMember 2025-03-28 0001114483 itgr:A2030ConvertibleSeniorNotesMember itgr:CappedCallOptionsMember 2026-04-03 0001114483 itgr:A2030ConvertibleSeniorNotesMember itgr:CappedCallOptionsMember 2025-03-28 0001114483 itgr:A2028ConvertibleSeniorNotesMember itgr:CappedCallOptionsMember 2026-01-01 2026-04-03 0001114483 itgr:A2030ConvertibleSeniorNotesMember us-gaap:ConvertibleDebtMember 2025-03-18 2025-03-18 0001114483 us-gaap:ResearchAndDevelopmentExpenseMember 2026-01-01 2026-04-03 0001114483 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-03-28 0001114483 itgr:RestructuringAndOtherChargesNetMember 2026-01-01 2026-04-03 0001114483 itgr:RestructuringAndOtherChargesNetMember 2025-01-01 2025-03-28 0001114483 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 2026-03-31 0001114483 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001114483 itgr:PerformanceBasedRSUsFinancialMember 2026-03-31 0001114483 itgr:PerformanceBasedRSUsFinancialMember 2026-03-31 2026-03-31 0001114483 itgr:PerformanceBasedRSUsMarketBasedMember 2026-03-31 0001114483 itgr:PerformanceBasedRSUsMarketBasedMember 2026-03-31 2026-03-31 0001114483 itgr:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2026-01-01 2026-04-03 0001114483 srt:DirectorMember itgr:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2026-01-01 2026-04-03 0001114483 itgr:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2025-12-31 0001114483 itgr:RestrictedStockAndRestrictedStockUnitsTimeBasedMember 2026-04-03 0001114483 srt:MinimumMember itgr:PerformanceBasedRSUsMember 2026-01-01 2026-04-03 0001114483 srt:MaximumMember itgr:PerformanceBasedRSUsMember 2026-01-01 2026-04-03 0001114483 itgr:PerformanceBasedRSUsMember 2026-01-01 2026-04-03 0001114483 itgr:PerformanceBasedRSUsMember 2025-12-31 0001114483 itgr:PerformanceBasedRSUsMember 2026-04-03 0001114483 itgr:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2026-01-01 2026-04-03 0001114483 itgr:RestrictedStockAndRestrictedStockUnitsPerformanceBasedMember 2025-01-01 2025-03-28 0001114483 itgr:OperationalExcellenceMember 2025-12-31 0001114483 itgr:StrategicReorganizationAndAlignmentMember 2025-12-31 0001114483 itgr:ManufacturingAlignmentToSupportGrowthMember 2025-12-31 0001114483 itgr:OperationalExcellenceMember 2026-01-01 2026-04-03 0001114483 itgr:StrategicReorganizationAndAlignmentMember 2026-01-01 2026-04-03 0001114483 itgr:ManufacturingAlignmentToSupportGrowthMember 2026-01-01 2026-04-03 0001114483 itgr:OperationalExcellenceMember 2026-04-03 0001114483 itgr:StrategicReorganizationAndAlignmentMember 2026-04-03 0001114483 itgr:ManufacturingAlignmentToSupportGrowthMember 2026-04-03 0001114483 us-gaap:ConvertibleDebtMember 2026-01-01 2026-04-03 0001114483 itgr:StockOptionsAndRestrictedStockUnitsMember 2026-01-01 2026-04-03 0001114483 itgr:StockOptionsAndRestrictedStockUnitsMember 2025-01-01 2025-03-28 0001114483 itgr:PerformanceBasedRSUsMember 2026-01-01 2026-04-03 0001114483 itgr:PerformanceBasedRSUsMember 2025-01-01 2025-03-28 0001114483 itgr:CommonStockIssuableUponConversionOfConvertibleNotesMember 2026-01-01 2026-04-03 0001114483 itgr:CommonStockIssuableUponConversionOfConvertibleNotesMember 2025-01-01 2025-03-28 0001114483 itgr:StockholdersEquityCommonStockIssuedMember 2025-12-31 0001114483 itgr:StockholdersEquityCommonStockOutstandingMember 2025-12-31 0001114483 itgr:StockholdersEquityCommonStockIssuedMember 2026-01-01 2026-04-03 0001114483 itgr:StockholdersEquityCommonStockOutstandingMember 2026-01-01 2026-04-03 0001114483 us-gaap:RestrictedStockUnitsRSUMember itgr:StockholdersEquityCommonStockIssuedMember 2026-01-01 2026-04-03 0001114483 us-gaap:RestrictedStockUnitsRSUMember itgr:StockholdersEquityCommonStockOutstandingMember 2026-01-01 2026-04-03 0001114483 itgr:StockholdersEquityCommonStockOutstandingMember 2025-01-01 2025-03-28 0001114483 itgr:StockholdersEquityCommonStockIssuedMember 2026-04-03 0001114483 itgr:StockholdersEquityCommonStockOutstandingMember 2026-04-03 0001114483 itgr:StockholdersEquityCommonStockIssuedMember 2024-12-31 0001114483 itgr:StockholdersEquityCommonStockOutstandingMember 2024-12-31 0001114483 itgr:StockholdersEquityCommonStockIssuedMember 2025-01-01 2025-03-28 0001114483 us-gaap:RestrictedStockUnitsRSUMember itgr:StockholdersEquityCommonStockIssuedMember 2025-01-01 2025-03-28 0001114483 us-gaap:RestrictedStockUnitsRSUMember itgr:StockholdersEquityCommonStockOutstandingMember 2025-01-01 2025-03-28 0001114483 itgr:StockholdersEquityCommonStockIssuedMember 2025-03-28 0001114483 itgr:StockholdersEquityCommonStockOutstandingMember 2025-03-28 0001114483 itgr:ShareRepurchaseProgramMember 2025-11-04 0001114483 itgr:ASRAgreementMember 2026-02-19 0001114483 itgr:ASRAgreementMember 2026-02-19 2026-02-19 0001114483 itgr:ASRAgreementMember 2026-04-02 2026-04-02 0001114483 itgr:ASRAgreementMember 2026-02-19 2026-04-02 0001114483 itgr:ShareRepurchaseProgramMember 2026-04-03 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2025-12-31 0001114483 itgr:AccumulatedAdjustmentAttributableToParentMember 2025-12-31 0001114483 itgr:AccumulatedOtherComprehensiveIncomeTaxAttributableToParentMember 2025-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-04-03 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-01-01 2026-04-03 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2026-01-01 2026-04-03 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2026-04-03 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2026-04-03 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2026-04-03 0001114483 itgr:AccumulatedAdjustmentAttributableToParentMember 2026-04-03 0001114483 itgr:AccumulatedOtherComprehensiveIncomeTaxAttributableToParentMember 2026-04-03 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-12-31 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0001114483 itgr:AccumulatedAdjustmentAttributableToParentMember 2024-12-31 0001114483 itgr:AccumulatedOtherComprehensiveIncomeTaxAttributableToParentMember 2024-12-31 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-28 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-01-01 2025-03-28 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-03-28 0001114483 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2025-03-28 0001114483 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2025-03-28 0001114483 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-28 0001114483 itgr:AccumulatedAdjustmentAttributableToParentMember 2025-03-28 0001114483 itgr:AccumulatedOtherComprehensiveIncomeTaxAttributableToParentMember 2025-03-28 0001114483 us-gaap:FairValueMeasurementsRecurringMember 2026-04-03 0001114483 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2026-04-03 0001114483 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2026-04-03 0001114483 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2026-04-03 0001114483 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001114483 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2025-12-31 0001114483 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2025-12-31 0001114483 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001114483 itgr:ForeignExchangeContractMaturingAprilTwoThousandTwentySevenContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingOctoberTwoThousandTwentySixContractOneMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingOctoberTwoThousandTwentySixContractTwoMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingDecemberTwoThousandTwentySixContractMember itgr:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingAprilTwoThousandTwentySevenContractOneMember itgr:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingAprilTwoThousandTwentySevenContractTwoMember itgr:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingAprilTwoThousandTwentySevenContractThreeMember itgr:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingJulyTwoThousandTwentySevenContractMember itgr:OtherLongTermLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2026-04-03 0001114483 itgr:ForeignExchangeContractMaturingOctoberTwoThousandTwentySixContractOneMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001114483 itgr:ForeignExchangeContractMaturingOctoberTwoThousandTwentySixContractTwoMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001114483 itgr:ForeignExchangeContractMaturingDecemberTwoThousandTwentySixContractMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001114483 itgr:ForeignExchangeContractMaturingOctoberTwoThousandTwentySixContractThreeMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001114483 itgr:ForeignExchangeContractMaturingAprilTwoThousandTwentySevenContractMember itgr:OtherLongTermLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001114483 itgr:ForeignExchangeContractMaturingDecemberTwoThousandTwentySixContractMember itgr:AccruedExpensesAndOtherCurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2025-12-31 0001114483 us-gaap:SalesMember 2026-01-01 2026-04-03 0001114483 us-gaap:SalesMember 2025-01-01 2025-03-28 0001114483 us-gaap:OperatingExpenseMember 2026-01-01 2026-04-03 0001114483 us-gaap:OperatingExpenseMember 2025-01-01 2025-03-28 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember 2026-01-01 2026-04-03 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:SalesMember 2025-01-01 2025-03-28 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2026-01-01 2026-04-03 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:CostOfSalesMember 2025-01-01 2025-03-28 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:OperatingExpenseMember 2026-01-01 2026-04-03 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:OperatingExpenseMember 2025-01-01 2025-03-28 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2026-04-03 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-12-31 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2026-01-01 2026-04-03 0001114483 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2025-01-01 2025-03-28 0001114483 itgr:PrecisionAndVSiMember 2026-04-03 0001114483 itgr:PrecisionAndVSiMember 2025-12-31 0001114483 srt:MaximumMember itgr:BiocoatIncorporatedMember 2026-04-03 0001114483 itgr:BiocoatIncorporatedMember 2026-04-03 0001114483 itgr:VSiParyleneInc.Member 2026-04-03 0001114483 itgr:InNeuroCoMember 2026-04-03 0001114483 itgr:LifeSciencesCompanyConvertibleDebtMember 2026-01-01 2026-04-03 0001114483 itgr:LifeSciencesCompanyConvertibleDebtMember 2026-04-03 0001114483 itgr:ChineseVentureCapitalFundMember 2026-04-03 0001114483 country:US 2026-04-03 0001114483 country:US 2025-12-31 0001114483 country:IE 2026-04-03 0001114483 country:IE 2025-12-31 0001114483 country:MX 2026-04-03 0001114483 country:MX 2025-12-31 0001114483 itgr:RestOfWorldMember 2026-04-03 0001114483 itgr:RestOfWorldMember 2025-12-31 0001114483 itgr:CardioAndVascularMember 2026-01-01 2026-04-03 0001114483 itgr:CardioAndVascularMember 2025-01-01 2025-03-28 0001114483 itgr:CardiacRhythmManagementNeuromodulationMember 2026-01-01 2026-04-03 0001114483 itgr:CardiacRhythmManagementNeuromodulationMember 2025-01-01 2025-03-28 0001114483 itgr:OtherMarketsMember 2026-01-01 2026-04-03 0001114483 itgr:OtherMarketsMember 2025-01-01 2025-03-28 0001114483 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:TransferredOverTimeMember 2026-01-01 2026-04-03 0001114483 us-gaap:ProductConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-03-28 0001114483 itgr:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 itgr:CustomerAMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-28 0001114483 itgr:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 itgr:CustomerBMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-28 0001114483 itgr:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 itgr:CustomerCMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-28 0001114483 itgr:AllOtherCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 itgr:AllOtherCustomersMember us-gaap:CustomerConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-28 0001114483 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 country:US us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-28 0001114483 country:CR us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 itgr:AllOtherCountriesMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2026-01-01 2026-04-03 0001114483 itgr:AllOtherCountriesMember us-gaap:GeographicConcentrationRiskMember us-gaap:RevenueFromContractWithCustomerMember 2025-01-01 2025-03-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________
FORM 10-Q
_____________________________________________________________

(Mark One) |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 3, 2026
or

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____
Commission File Number 1-16137
_____________________________________________________________
INTEGER HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
_____________________________________________________________

Delaware |  | 16-1531026
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)

5830 Granite Parkway, | Suite 1150 | Plano, | Texas |  | 75024
(Address of principal executive offices) |  | (Zip Code)

(214) 618-5243
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.001 par value per share |  | ITGR |  | New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by checkmark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  | Accelerated filer | ☐ |  | Non-accelerated filer | ☐
Smaller reporting company | ☐ |  | Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares outstanding of the Company’s common stock, $0.001 par value per share, as of April 24, 2026 was: 33,954,839 shares.

INTEGER HOLDINGS CORPORATION
Form 10-Q
For the Quarterly Period Ended April 3, 2026
TABLE OF CONTENTS

|  | Page
PART I—FINANCIAL INFORMATION |
ITEM 1. | Financial Statements | 3 |
| Condensed Consolidated Balance Sheets (Unaudited) | 3 |
| Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) | 4 |
| Condensed Consolidated Statements of Cash Flows (Unaudited) | 5 |
| Condensed Consolidated Statements of Stockholders’ Equity (Unaudited) | 6 |
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 7 |
ITEM 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 30 |
ITEM 3. | Quantitative and Qualitative Disclosures About Market Risk | 43 |
ITEM 4. | Controls and Procedures | 43 |
PART II—OTHER INFORMATION |
ITEM 1. | Legal Proceedings | 44 |
ITEM 1A. | Risk Factors | 44 |
ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 45 |
ITEM 5. | Other Information | 45 |
ITEM 6. | Exhibits | 46 |
SIGNATURES | 47 |

- 2 -

Table of Contents
PART I—FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
INTEGER HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)

(in thousands except share and per share data) | April 3, 2026 |  | December 31, 2025
ASSETS |  |  |
Current assets: |  |  |
Cash and cash equivalents | $ | 8,115 |  |  | $ | 17,161 |
Accounts receivable, net of provision for credit losses of $0.6 million and $0.6 million, respectively | 327,776 |  |  | 346,079 |
Inventories | 284,475 |  |  | 253,739 |
Contract assets | 115,727 |  |  | 112,546 |
Prepaid expenses and other current assets | 38,671 |  |  | 40,572 |
Total current assets | 774,764 |  |  | 770,097 |
Property, plant and equipment, net | 533,144 |  |  | 536,427 |
Goodwill | 1,106,767 |  |  | 1,110,908 |
Other intangible assets, net | 806,335 |  |  | 825,435 |
Deferred income taxes | 8,983 |  |  | 8,994 |
Operating lease assets | 85,098 |  |  | 98,437 |
Financing lease assets | 57,071 |  |  | 37,109 |
Other long-term assets | 39,557 |  |  | 23,170 |
Total assets | $ | 3,411,719 |  |  | $ | 3,410,577 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |  |
Current liabilities: |  |  |
Accounts payable | $ | 115,001 |  |  | $ | 113,130 |
Operating lease liabilities | 8,111 |  |  | 9,099 |
Accrued expenses and other current liabilities | 83,232 |  |  | 109,812 |
Total current liabilities | 206,344 |  |  | 232,041 |
Long-term debt | 1,251,527 |  |  | 1,185,179 |
Deferred income taxes | 115,099 |  |  | 116,327 |
Operating lease liabilities | 69,291 |  |  | 81,899 |
Financing lease liabilities | 52,530 |  |  | 28,578 |
Other long-term liabilities | 20,036 |  |  | 19,910 |
Total liabilities | 1,714,827 |  |  | 1,663,934 |
Stockholders’ equity: |  |  |
Common stock, $0.001 par value; 100,000,000 shares authorized; 35,481,805 and 35,481,805 shares issued, respectively; 33,945,540 and 34,346,450 shares outstanding, respectively | 35 |  |  | 35 |
Additional paid-in capital | 755,873 |  |  | 771,223 |
Treasury stock, at cost; 1,536,265 shares and 1,135,355 shares, respectively | (114,234) |  |  | (76,872) |
Retained earnings | 1,010,561 |  |  | 994,055 |
Accumulated other comprehensive income | 44,657 |  |  | 58,202 |
Total stockholders’ equity | 1,696,892 |  |  | 1,746,643 |
Total liabilities and stockholders’ equity | $ | 3,411,719 |  |  | $ | 3,410,577 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -

Table of Contents
INTEGER HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (Unaudited)

| Three Months Ended |  |
(in thousands except per share data) | April 3, 2026 |  | March 28, 2025 |  |  |  |
Sales | $ | 439,580 |  |  | $ | 437,392 |  |  |  |  |
Cost of sales | 329,985 |  |  | 317,074 |  |  |  |  |
Gross profit | 109,595 |  |  | 120,318 |  |  |  |  |
Operating expenses: |  |  |  |  |  |  |
Selling, general and administrative | 58,711 |  |  | 51,160 |  |  |  |  |
Research, development and engineering | 16,243 |  |  | 14,201 |  |  |  |  |
Restructuring and other charges | 2,772 |  |  | 5,405 |  |  |  |  |
Total operating expenses | 77,726 |  |  | 70,766 |  |  |  |  |
Operating income | 31,869 |  |  | 49,552 |  |  |  |  |
Interest expense | 9,734 |  |  | 14,805 |  |  |  |  |
(Gain) loss on equity investments | 1,468 |  |  | (181) |  |  |  |  |
Other loss, net (see Note 6) | 316 |  |  | 47,927 |  |  |  |  |
Income from continuing operations before taxes | 20,351 |  |  | (12,999) |  |  |  |  |
Provision for income taxes | 3,845 |  |  | 9,466 |  |  |  |  |
Income (loss) from continuing operations | 16,506 |  |  | (22,465) |  |  |  |  |
Loss from discontinued operations, net of tax | — |  |  | (22) |  |  |  |  |
Net income (loss) | $ | 16,506 |  |  | $ | (22,487) |  |  |  |  |
Basic earnings (loss) per share: |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 0.48 |  |  | $ | (0.66) |  |  |  |  |
Loss from discontinued operations | — |  |  | — |  |  |  |  |
Basic earnings (loss) per share | 0.48 |  |  | (0.66) |  |  |  |  |
Diluted earnings (loss) per share: |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 0.48 |  |  | $ | (0.66) |  |  |  |  |
Loss from discontinued operations | — |  |  | — |  |  |  |  |
Diluted earnings (loss) per share | 0.48 |  |  | (0.66) |  |  |  |  |
Weighted average shares outstanding: |  |  |  |  |  |  |
Basic | 34,278 |  |  | 33,916 |  |  |  |  |
Diluted | 34,433 |  |  | 33,916 |  |  |  |  |
Comprehensive Income |  |  |  |  |  |  |
Net income (loss) | $ | 16,506 |  |  | $ | (22,487) |  |  |  |  |
Other comprehensive income (loss): |  |  |  |  |  |  |
Foreign currency translation gain (loss) | (10,654) |  |  | 20,291 |  |  |  |  |
Change in fair value of cash flow hedges, net of tax | (2,891) |  |  | 4,498 |  |  |  |  |
Other comprehensive income (loss) | (13,545) |  |  | 24,789 |  |  |  |  |
Comprehensive income | $ | 2,961 |  |  | $ | 2,302 |  |  |  |  |

The accompanying notes are an integral part of these condensed consolidated financial statements.
- 4 -

Table of Contents
INTEGER HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

| Three Months Ended
(in thousands) | April 3, 2026 |  | March 28, 2025
Cash flows from operating activities: |  |  |
Net income (loss) | $ | 16,506 |  |  | $ | (22,487) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
Depreciation and amortization | 35,011 |  |  | 29,832 |
Debt related charges included in interest expense | 1,625 |  |  | 1,882 |
Debt conversion inducement expense | — |  |  | 46,681 |
Stock-based compensation | 6,662 |  |  | 6,880 |
Non-cash lease expense | 2,452 |  |  | 2,455 |
Non-cash gain on equity investments | 1,468 |  |  | (181) |
Other non-cash losses | 716 |  |  | 2,574 |
Deferred income taxes | 17 |  |  | 4,055 |
Gain on sale of discontinued operations | — |  |  | (46) |
Changes in operating assets and liabilities, net of acquisitions: |  |  |
Accounts receivable | 18,583 |  |  | (18,232) |
Inventories | (32,386) |  |  | (7,695) |
Prepaid expenses and other assets | (2,843) |  |  | (1,169) |
Contract assets | (3,313) |  |  | 1,219 |
Accounts payable | 9,440 |  |  | 10,207 |
Accrued expenses and other liabilities | (30,647) |  |  | (23,495) |
Income taxes | 1,404 |  |  | (1,204) |
Net cash provided by operating activities | 24,695 |  |  | 31,276 |
Cash flows from investing activities: |  |  |
Acquisition of property, plant and equipment | (23,958) |  |  | (25,218) |
Proceeds from sale of property, plant and equipment | 55 |  |  | 5 |
Purchase of equity and other investments, net of distributions | (13,998) |  |  | — |
Acquisitions, net of cash acquired | — |  |  | (171,954) |
Net cash used in investing activities | (37,901) |  |  | (197,167) |
Cash flows from financing activities: |  |  |
Principal payments of long-term debt | — |  |  | (613,683) |
Proceeds from issuance of convertible notes, net of discount | — |  |  | 977,500 |
Proceeds from revolving credit facility | 111,800 |  |  | 216,000 |
Payments of revolving credit facility | (46,800) |  |  | (342,000) |
Purchase of capped calls | — |  |  | (71,000) |
Repurchases of common stock | (50,000) |  |  | — |
Tax withholdings related to net share settlements of restricted stock unit awards | (9,035) |  |  | (14,132) |
Principal payments on finance leases | (2,029) |  |  | (1,177) |
Other financing activities | (106) |  |  | 70 |
Net cash provided by financing activities | 3,830 |  |  | 151,578 |
Effect of foreign currency exchange rates on cash and cash equivalents | 330 |  |  | (519) |
Net decrease in cash and cash equivalents | (9,046) |  |  | (14,832) |
Cash and cash equivalents, beginning of period | 17,161 |  |  | 46,543 |
Cash and cash equivalents, end of period | $ | 8,115 |  |  | $ | 31,711 |

The accompanying notes are an integral part of these condensed consolidated financial statements.
- 5 -

Table of Contents
INTEGER HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Unaudited)

| Three Months Ended |  |
(in thousands) | April 3, 2026 |  | March 28, 2025 |  |  |  |
Total stockholders’ equity, beginning balance | $ | 1,746,643 |  |  | $ | 1,619,215 |  |  |  |  |
Common stock and additional paid-in capital |  |  |  |  |  |  |
Balance, beginning of period | 771,258 |  |  | 742,011 |  |  |  |  |
Stock awards exercised or vested | (22,012) |  |  | (14,107) |  |  |  |  |
Stock-based compensation | 6,662 |  |  | 6,880 |  |  |  |  |
Capped calls related to the issuance of 2030 Notes, net of tax | — |  |  | (53,130) |  |  |  |  |
Partial conversion of convertible notes due 2028 Notes and partial unwind of related capped calls, net of tax | — |  |  | 68,413 |  |  |  |  |
Issuance of common stock for acquisition | — |  |  | 3,989 |  |  |  |  |
Balance, end of period | 755,908 |  |  | 754,056 |  |  |  |  |
Treasury stock |  |  |  |  |  |  |
Balance, beginning of period | (76,872) |  |  | — |  |  |  |  |
Treasury shares purchased, including excise tax for 2026 | (50,339) |  |  | (26,858) |  |  |  |  |
Treasury shares reissued | 12,977 |  |  | — |  |  |  |  |
Balance, end of period | (114,234) |  |  | (26,858) |  |  |  |  |
Retained earnings |  |  |  |  |  |  |
Balance, beginning of period | 994,055 |  |  | 891,247 |  |  |  |  |
Net income | 16,506 |  |  | (22,487) |  |  |  |  |
Balance, end of period | 1,010,561 |  |  | 868,760 |  |  |  |  |
Accumulated other comprehensive income |  |  |  |  |  |  |
Balance, beginning of period | 58,202 |  |  | (14,043) |  |  |  |  |
Other comprehensive income (loss) | (13,545) |  |  | 24,789 |  |  |  |  |
Balance, end of period | 44,657 |  |  | 10,746 |  |  |  |  |
Total stockholders’ equity, ending balance | $ | 1,696,892 |  |  | $ | 1,606,704 |  |  |  |  |

The accompanying notes are an integral part of these condensed consolidated financial statements.
- 6 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(1.) BASIS OF PRESENTATION
Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly-traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is a medical device contract development and manufacturing organization, primarily serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. The Company’s primary customers include large, multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.
The accompanying condensed consolidated financial statements are presented in accordance with the rules and regulations of the United States (“U.S.”) Securities and Exchange Commission (“SEC”) and do not include all of the disclosures normally required by U.S. generally accepted accounting principles (“U.S. GAAP”) as contained in the Company’s Annual Report on Form 10-K. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2025.
In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. The results for interim periods are not necessarily indicative of results or trends that may be expected for the fiscal year as a whole. The condensed consolidated financial statements were prepared using U.S. GAAP, which requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
The first quarters of 2026 and 2025 ended on April 3, 2026 and March 28, 2025, respectively, and consisted of 93 days and 87 days, respectively.
Discontinued Operations
The Company sold Electrochem Solutions, Inc. (“Electrochem”) during the fourth quarter of 2024. The results of operations of the Electrochem business are classified as discontinued operations. There has been no activity from discontinued operations since an immaterial non-cash loss in the first quarter of 2025.
Recent Accounting Pronouncements
In the normal course of business, management evaluates all new Accounting Standards Updates (“ASU”) and other accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), SEC, or other authoritative accounting bodies to determine the potential impact they may have on the financial position, results of operations or cash flows of the Company. Other than those discussed below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material effect on the financial position, results of operations or cash flows of the Company.
Accounting Guidance to be Adopted in Future Periods
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The ASU is intended to improve disclosures about a public business entity’s expense and provide more detailed information to investors about the types of expenses in commonly presented expense captions. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The ASU will affect only the Company’s disclosures and will not impact its results of operations or financial condition. The Company is currently evaluating the timing of its adoption.
- 7 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(2.) BUSINESS ACQUISITIONS
2025 Acquisitions
Precision Coating LLC Acquisition
On January 7, 2025, the Company acquired substantially all of the assets and assumed certain liabilities of certain subsidiaries of Katahdin Industries, Inc., including its main operating subsidiary, Precision Coating LLC (collectively “Precision”). Prior to the acquisition, Precision was a privately-held manufacturer specializing in high value surface coating technology platforms, including fluoropolymer, anodic coatings, ion treatment solutions and laser processing.
The total consideration transferred was $153.5 million, including contingent consideration, working capital and other purchase price adjustments. The Company recorded contingent consideration with an estimated acquisition date fair value of $1.4 million, representing the Company’s obligation, under the purchase agreement, to make an additional payment of up to $5.0 million based on a specified revenue growth milestone being met in 2025. The revenue growth milestone for Precision was not met for 2025, and the Company determined that no additional consideration was required to be paid.
VSi Parylene Acquisition
On February 28, 2025, the Company acquired substantially all of the assets and assumed certain liabilities of Vertical Solutions, Inc., d/b/a VSi Parylene (“VSi”). Prior to the acquisition VSi was a privately-held full-service provider of parylene coating solutions, primarily focused on complex medical device applications.
The total consideration transferred was $24.0 million, including shares of Integer’s common stock (“Common Stock”) with a fair value of $4.0 million, contingent consideration, working capital and other purchase price adjustments. The Company recorded contingent consideration with an estimated acquisition date fair value of $1.1 million, representing the Company’s obligation, under the purchase agreement, to make additional payments of up to $4.0 million, in the aggregate, based on specified annual revenue growth milestones being met through 2028. See Note 13, “Financial Instruments and Fair Value Measurements,” for additional information related to the fair value measurement of the contingent consideration.
Biocoat Incorporated
On December 4, 2025, the Company acquired certain assets of Biocoat Incorporated (“Biocoat”). Prior to the acquisition, Biocoat was a privately-held manufacturer specializing in high value surface coating technology platforms, including UV and thermal cure hydrophilic coatings.
The total consideration transferred was $15.0 million, including contingent consideration, working capital and other purchase price adjustments. The Company recorded contingent consideration with an estimated acquisition date fair value of $7.0 million, representing the Company’s obligation, under the purchase agreement, to make an additional payment of up to $7.0 million based on specified operational milestones being met after close. See Note 13, “Financial Instruments and Fair Value Measurements,” for additional information related to the fair value measurement of the contingent consideration.
The Company has finalized the purchase price allocation for Precision and VSi and has preliminarily estimated fair values for the assets purchased and liabilities assumed as of the date of the Biocoat acquisition. The determination of estimated fair value required management to make significant estimates and assumptions based on information that was available at the time that the condensed consolidated financial statements were prepared. The amounts reported are considered preliminary as the Company is completing the valuations that are required to allocate the purchase prices in areas such as property and equipment, intangible assets, liabilities and goodwill. As a result, the preliminary allocation of the purchase price may change in the future, including in ways which could be material.
During the first quarter of 2026, certain immaterial measurement period adjustments related to Biocoat were made which resulted in a decrease to property, plant and equipment and an increase to other noncurrent assets. These measurement period adjustments resulted in an immaterial decrease in goodwill when compared to the balance as of December 31, 2025. The changes to the preliminary fair value estimates resulting from the measurement period adjustments recorded during the first quarter of 2026 did not have a material impact to the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income.
- 8 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(2.) BUSINESS ACQUISITIONS (Continued)
The following table summarizes the final purchase price for Precision and VSi and preliminary purchase price allocation for Biocoat (in thousands):

| Precision |  | VSi |  | Biocoat |  | Total
Fair value of net assets acquired |  |  |  |  |  |  |
Current assets (excluding inventory) | $ | 11,609 |  |  | $ | 1,982 |  |  | $ | — |  |  | $ | 13,591 |
Inventory | 4,019 |  |  | 1,018 |  |  | — |  |  | 5,037 |
Property, plant and equipment | 13,674 |  |  | 2,732 |  |  | 1,020 |  |  | 17,426 |
Goodwill | 50,823 |  |  | 5,265 |  |  | 10,334 |  |  | 66,422 |
Intangible assets: |  |  |  |  |  |  |
Customer relationships | 52,000 |  |  | 7,700 |  |  | 520 |  |  | 60,220 |
Technology | 20,700 |  |  | 5,900 |  |  | 3,100 |  |  | 29,700 |
Operating lease assets | 13,862 |  |  | 1,505 |  |  | 128 |  |  | 15,495 |
Other noncurrent assets | 43 |  |  | — |  |  | 32 |  |  | 75 |
Current liabilities | (4,341) |  |  | (883) |  |  | (87) |  |  | (5,311) |
Operating lease liabilities (noncurrent) | (8,922) |  |  | (1,256) |  |  | (47) |  |  | (10,225) |
Fair value of net assets acquired | $ | 153,467 |  |  | $ | 23,963 |  |  | $ | 15,000 |  |  | $ | 192,430 |

- 9 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(3.) SUPPLEMENTAL FINANCIAL STATEMENT DISCLOSURES
Supplemental Cash Flow Information
The following is supplemental information, including discontinued operations, relating to the Condensed Consolidated Statements of Cash Flows (in thousands):

| Three Months Ended
| April 3, 2026 |  | March 28, 2025
Noncash investing and financing activities: |  |  |
Property, plant and equipment purchases included in accounts payable | $ | 8,840 |  |  | $ | 16,701 |
Accrued excise tax associated with share repurchases | 339 |  |  | — |
Common stock issued for conversion of debt | — |  |  | 183,972 |
Common stock received under capped call upon conversion of debt | — |  |  | 26,858 |
Write-off of unamortized deferred costs and original issued discount upon conversion of debt included in Additional paid in capital | — |  |  | 5,124 |
Common stock issued for acquisition | — |  |  | 3,989 |
Debt issuance costs incurred but not yet paid | — |  |  | 1,208 |
Supplemental lease disclosures: |  |  |
Assets acquired under operating leases | 309 |  |  | 11,147 |
Assets acquired under finance leases | 21,702 |  |  | 3,159 |

Factoring Arrangements
The Company has receivable factoring arrangements, pursuant to which certain receivables may be sold on a non-recourse basis to financial institutions. Factoring fees are recorded in Selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income. During the three months ended April 3, 2026 and March 28, 2025, the Company sold accounts receivable of $10.1 million and $58.1 million, respectively, and recorded factoring fees of $0.1 million and $0.4 million, respectively.
Supplier Financing Arrangements
The Company utilizes supplier financing arrangements with financial institutions to sell certain accounts receivable on a non-recourse basis. Fees for supplier financing arrangements are recorded in Selling, general, and administrative expenses in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income. During the three months ended April 3, 2026 and March 28, 2025, the Company sold and de-recognized accounts receivable of $41.8 million and $39.9 million, respectively, and recorded costs associated with the supplier financing arrangements of $0.5 million and $0.5 million, respectively.
(4.) INVENTORIES
Inventories comprise the following (in thousands):

| April 3, 2026 |  | December 31, 2025
Raw materials | $ | 104,082 |  |  | $ | 94,131 |
Work-in-process | 157,032 |  |  | 143,467 |
Finished goods | 23,361 |  |  | 16,141 |
Total | $ | 284,475 |  |  | $ | 253,739 |

- 10 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(5.) GOODWILL AND OTHER INTANGIBLE ASSETS, NET
Goodwill
The changes in the carrying amount of goodwill for the three months ended April 3, 2026 were as follows (in thousands):

| Medical |  |  |  |
December 31, 2025 | $ | 1,110,908 |  |  |  |  |
Biocoat acquisition-related adjustments (Note 2) | (10) |  |  |  |  |
Foreign currency translation | (4,131) |  |  |  |  |
April 3, 2026 | $ | 1,106,767 |  |  |  |  |

Intangible Assets
Intangible assets comprise the following (in thousands):

| Gross Carrying Amount |  | Accumulated Amortization |  |  |  | Net Carrying Amount
April 3, 2026 |  |  |  |  |  |  |
Definite-lived: |  |  |  |  |  |  |
Purchased technology and patents | $ | 328,635 |  |  | $ | (232,600) |  |  |  |  | $ | 96,035 |
Customer lists | 953,172 |  |  | (344,555) |  |  |  |  | 608,617 |
Amortizing tradenames and other | 20,070 |  |  | (8,675) |  |  |  |  | 11,395 |
Total amortizing intangible assets | $ | 1,301,877 |  |  | $ | (585,830) |  |  |  |  | $ | 716,047 |
Indefinite-lived: |  |  |  |  |  |  |
Trademarks and tradenames |  |  |  |  |  |  | $ | 90,288 |
December 31, 2025 |  |  |  |  |  |  |
Definite-lived: |  |  |  |  |  |  |
Purchased technology and patents | $ | 329,690 |  |  | $ | (228,469) |  |  |  |  | $ | 101,221 |
Customer lists | 957,239 |  |  | (334,989) |  |  |  |  | 622,250 |
Amortizing tradenames and other | 20,083 |  |  | (8,407) |  |  |  |  | 11,676 |
Total amortizing intangible assets | $ | 1,307,012 |  |  | $ | (571,865) |  |  |  |  | $ | 735,147 |
Indefinite-lived: |  |  |  |  |  |  |
Trademarks and tradenames |  |  |  |  |  |  | $ | 90,288 |

Aggregate intangible asset amortization expense comprises the following (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Cost of sales | $ | 4,837 |  |  | $ | 4,574 |  |  |  |  |
Selling, general and administrative expenses | 11,157 |  |  | 10,277 |  |  |  |  |
Total intangible asset amortization expense | $ | 15,994 |  |  | $ | 14,851 |  |  |  |  |

Estimated future intangible asset amortization expense based on the carrying value as of April 3, 2026 is as follows (in thousands):

| Remainder of 2026 |  | 2027 |  | 2028 |  | 2029 |  | 2030 |  | After 2030
Amortization Expense | $ | 47,238 |  |  | $ | 60,317 |  |  | $ | 58,804 |  |  | $ | 56,548 |  |  | $ | 53,045 |  |  | $ | 440,095 |

- 11 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(6.) DEBT
Long-term debt comprises the following (in thousands):

| April 3, 2026 |  | December 31, 2025
| Principal Amount |  | Unamortized Discounts and Issuance Costs |  | Net Carrying Amount |  | Principal Amount |  | Unamortized Discounts and Issuance Costs |  | Net Carrying Amount
Senior Secured Credit Facilities: |  |  |  |  |  |  |  |  |  |  |
Revolving credit facilities | $ | 65,000 |  |  | $ | — |  |  | $ | 65,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Term loan A | 91,000 |  |  | (197) |  |  | 90,803 |  |  | 91,000 |  |  | (221) |  |  | 90,779 |
2028 Notes | 116,284 |  |  | (1,369) |  |  | 114,915 |  |  | 116,284 |  |  | (1,542) |  |  | 114,742 |
2030 Notes | 1,000,000 |  |  | (19,191) |  |  | 980,809 |  |  | 1,000,000 |  |  | (20,342) |  |  | 979,658 |
Total | $ | 1,272,284 |  |  | $ | (20,757) |  |  | $ | 1,251,527 |  |  | $ | 1,207,284 |  |  | $ | (22,105) |  |  | $ | 1,185,179 |
Current portion of long-term debt |  |  |  |  | — |  |  |  |  |  |  | — |
Long-term debt |  |  |  |  | $ | 1,251,527 |  |  |  |  |  |  | $ | 1,185,179 |

The Company’s debt structure includes senior secured credit facilities (the “Senior Secured Credit Facilities”), unsecured 2.125% Convertible Senior Notes due in 2028 (the “2028 Notes”), and unsecured 1.875% Convertible Senior Notes due in 2030 (the “2030 Notes,” and together with the 2028 Notes, the “Convertible Notes”). For additional details regarding the Company’s debt financing, refer to Note 9, “Debt” of the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Senior Secured Credit Facilities
In September 2021, the Company entered into a credit agreement (the “2021 Credit Agreement”), governing the Senior Secured Credit Facilities. As of April 3, 2026, the Company maintained Senior Secured Credit Facilities consisting of a five-year $800 million revolving credit facility (the “Revolving Credit Facility”) and a five-year “term A” loan (the “TLA Facility”). A portion of the Revolving Credit Facility is available for swingline loans of up to a sublimit of $75 million and for the issuance of standby letters of credit of up to a sublimit of $40 million.
Revolving Credit Facility
The Revolving Credit Facility matures on February 15, 2028, and provides for revolving loans in an aggregate amount of $800 million. As of April 3, 2026, the Company had available borrowing capacity on the Revolving Credit Facility of $729.7 million after giving effect to outstanding borrowings and $5.3 million of outstanding standby letters of credit. Borrowings under the Revolving Credit Facility bear interest at a rate based on the secured overnight financing rate (“SOFR”) for the applicable interest period plus an adjustment of 0.10% per annum, in relation to any loan in U.S. dollars, and the Euro Interbank Offered Rate, in relation to any loan in Euros, plus a margin based on the Company’s Secured Net Leverage Ratio (as defined in the 2021 Credit Agreement). Swingline loans bear interest at a rate based on SOFR plus a margin based on the Company’s Secured Net Leverage Ratio. In addition, the Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which ranges between 0.15% and 0.25%, depending on the Company’s Secured Net Leverage Ratio. As of April 3, 2026, the commitment fee on the unused portion of the Revolving Credit Facility was 0.15%. As of April 3, 2026, the interest rate on the Revolving Credit Facility was 5.01%.
On March 25, 2026, the Company entered into a fifth amendment (the “Fifth Amendment”) to the 2021 Credit Agreement. The Fifth Amendment amended the terms of the 2021 Credit Agreement to, among other things, increase the portion of the Revolving Credit Facility that is available for swingline loans up to a sublimit of $75 million and to permit swingline loans to bear interest, at the Company’s option, at a rate based on SOFR plus a margin.
TLA Facility
The TLA Facility matures on February 15, 2028. During 2025, the Company prepaid the required quarterly principal installments under the TLA Facility through maturity. The interest rate terms for the TLA Facility are the same as those described above for the Revolving Credit Facility borrowings in U.S. dollars. As of April 3, 2026, the interest rate on the TLA Facility was 5.01%.
Contractual principal maturities under the Senior Secured Credit Facilities as of April 3, 2026, are as follows (in thousands):

|  | Remainder of 2026 |  | 2027 |  | 2028 |  |  |  |  |  |
Future minimum principal payments |  | $ | — |  |  | $ | — |  |  | $ | 156,000 |  |  |  |  |  |  |

- 12 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(6.) DEBT (Continued)
Covenants
The 2021 Credit Agreement contains customary terms and conditions, including representations and warranties and affirmative and negative covenants, as well as financial covenants for the benefit of the lenders under the Revolving Credit Facility and the TLA Facility, which require the Company not to exceed a specified maximum Total Net Leverage Ratio (as defined in the 2021 Credit Agreement) and an interest coverage ratio as of the end of each fiscal quarter. As of April 3, 2026, the Company was in compliance with these financial covenants.
Convertible Notes
The following table summarizes certain terms related to the Company’s current outstanding Convertible Notes:

Convertible Notes |  | Maturity Date |  | Annual Coupon Rate |  | Annual Effective Interest Rate |  | Payment Dates for Semi-Annual Interest Payments in Arrears |  |
2028 Notes |  | February 15, 2028 |  | 2.125% |  | 2.76% |  | February 15 and August 15 |  |
2030 Notes |  | March 15, 2030 |  | 1.875% |  | 2.38% |  | March 15 and September 15 |  |

Conversion and Redemption Terms of the Notes
The Company’s Notes will mature at their maturity date unless earlier repurchased, redeemed or converted. The Convertible Notes’ initial conversion terms are summarized below:

Convertible Notes |  | Free Convertibility Date |  | Initial Conversion Rate per $1,000 Principal |  | Initial Conversion Price |  | Redemption Date |  |
2028 Notes |  | November 15, 2027 |  | 11.4681 |  | $87.20 |  | February 20, 2026 |  |
2030 Notes |  | December 15, 2029 |  | 6.6243 |  | $150.96 |  | March 20, 2028 |  |

The conversion rate is subject to standard anti-dilutive adjustments and adjustments upon the occurrence of specified events.
The Company will settle conversions of the Convertible Notes by paying cash up to the aggregate principal amount of the applicable Convertible Notes to be converted, and cash, shares of Common Stock or a combination thereof, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the aggregate principal amount of the Convertible Notes being converted. The holders of the Convertible Notes may convert all or a portion of such Notes, in multiples of $1,000 principal amounts, prior to certain specified dates (each, a “Free Convertibility Date”) only under the following circumstances (in each case, as applicable to each series of Convertible Notes):
•during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the Common Stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% (for the 2028 Notes) and 150% (for the 2030 Notes) of the conversion price on each applicable trading day;
•during the five business day period after any ten consecutive trading day period (the “Measurement Period”) in which the trading price (as defined in the applicable indenture) per $1,000 principal amount of the notes for each trading day of the Measurement Period was less than 98% of the product of the last reported sale price of the Common Stock and the conversion rate in effect on each such trading day;
•if the Company calls any or all of the notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date; or
•upon the occurrence of specified corporate events (as set forth in the applicable indenture).
On or after the applicable Free Convertibility Date until the close of business on the second scheduled trading day immediately preceding the applicable maturity date, holders of the Convertible Notes may convert all or any portion of the Convertible Notes at their option at the conversion rate then in effect, regardless of the foregoing circumstances.
The conditional conversion features of the 2028 Notes and 2030 Notes were not triggered during the calendar quarter ended March 31, 2026, therefore, the 2028 Notes and 2030 Notes are not convertible during the calendar quarter ended June 30, 2026 pursuant to the applicable last reported sales price conditions.
- 13 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(6.) DEBT (Continued)
If the Company undergoes a fundamental change (as defined in the applicable indenture), subject to certain conditions, holders may require the Company to repurchase for cash all or any portion of such Notes, in principal amounts of $1,000 or a multiple thereof, at a fundamental change repurchase price equal to 100% of the principal amount of such Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. In addition, following certain corporate events or if the Company issues a notice of redemption, it will, under certain circumstances, increase the conversion rate for holders who elect to convert their Notes in connection with such corporate event or during the relevant redemption period.
The Company may not redeem the Convertible Notes prior to certain dates (the “Redemption Date”). On or after the applicable Redemption Date, the Company may redeem for cash all or any portion of the Convertible Notes if the last reported sale price of its Common Stock has been at least 130% (for the 2028 Notes) and 140% (for the 2030 Notes) of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending not more than two trading days immediately preceding the date on which the Company provides notice of redemption at a redemption price equal to 100% of the principal amount of the of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the Redemption Date (as defined in the 2030 Notes Indenture).
Convertible Notes Exchange Transactions
On March 18, 2025, the Company used a portion of the remaining net proceeds from the issuance of the 2030 Notes to exchange $383.7 million in aggregate principal amount of the 2028 Notes for an aggregate cash exchange consideration of $384.4 million in cash and 1,553,806 shares of Common Stock (the “Note Exchange Transactions”). The Note Exchange Transactions were considered an induced conversion and, as a result, the Company recorded $46.7 million during the first quarter of 2025 in induced conversion expense within Other loss, net in the Consolidated Statements of Operations. Contemporaneously with the Note Exchange Transactions, the Company terminated a portion of the capped call transactions related to the 2028 Notes and received 436,963 shares of common stock.
Fair Value of the Notes
As of April 3, 2026, the estimated fair value of the 2028 Notes and 2030 Notes was approximately $137.4 million and $956.9 million, respectively. As of December 31, 2025, the estimated fair value of the 2028 Notes and 2030 Notes was approximately $131.5 million and $930.0 million, respectively. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. The fair value of the Convertible Notes is categorized in Level 2 of the fair value hierarchy.
Capped Calls
In connection with the issuance of the 2028 Notes and 2030 Notes, the Company entered into privately negotiated capped calls (the “2028 Capped Calls” and “2030 Capped Calls”) (collectively, the “Capped Calls”) with certain financial institutions. The Capped Calls are generally expected to reduce the potential dilution and/or offset the cash payments the Company is required to make in excess of the principal amount of converted Convertible Notes if the market price per share of the Company’s Common Stock is greater than the strike price of the applicable Capped Call (which corresponds to the initial conversion price of the applicable Convertible Notes and is subject to certain adjustments under the terms of the applicable Capped Call), with such reduction and/or offset subject to a cap based on the cap price of the applicable Capped Calls (the “Initial Cap Price”).
Each of the Capped Calls has an initial cap price per share of the Company’s Common Stock, which represented a premium over the last reported sale price of the Company’s Common Stock on the date the corresponding Convertible Notes were priced, and is subject to certain adjustments under the terms of the corresponding agreements. Collectively, the Capped Calls cover, initially, the number of shares of Common Stock underlying the Convertible Notes, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes.
The initial terms for the Capped Calls are presented below:

Capped Calls |  | Maturity Date |  | Initial Strike Price |  | Initial Cap Price |  |  |  |  |  |
2028 Capped Calls |  | February 15, 2028 |  | $87.20 |  | $108.59 |  |  |  |  |  |
2030 Capped Calls |  | March 15, 2030 |  | $150.96 |  | $189.44 |  |  |  |  |  |

- 14 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(6.) DEBT (Continued)
For accounting purposes, the Capped Calls are separate transactions, and not integrated with the issuance of the Convertible Notes. As these transactions meet certain accounting criteria, the Capped Calls are recorded in stockholders’ equity and are not accounted for as derivatives. The Convertible Notes and the Capped Calls will be integrated for tax purposes. The accounting impact of this tax treatment results in the Capped Calls being deductible as original issue discount for tax purposes over the term of the Convertible Notes, generating a deferred tax asset which is recognized through equity. The premiums paid for the Capped Calls were recorded, net of a deferred tax asset, as a reduction to additional paid-in capital. when they were entered.
A portion of the 2028 Capped Calls were terminated in conjunction with the Note Exchange Transactions. The fair value of the terminated portion of the 2028 Capped Calls was $26.9 million, which was recorded as an increase to additional paid-in capital. The Company also recorded income tax expense of $4.1 million and a corresponding reduction to the deferred tax asset associated with the terminated portion of the 2028 Capped Calls.
(7.) STOCK-BASED COMPENSATION
The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors (the “Board”) or the Compensation and Organization Committee (the “Compensation Committee”) of the Board. The stock-based compensation plans provide for the granting of stock options, restricted stock awards, performance awards, time-based restricted stock units (“RSUs”), performance-based RSUs (“PRSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers.
Stock-based Compensation Expense
The classification of stock-based compensation expense was as follows (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Cost of sales | $ | 1,408 |  |  | $ | 1,423 |  |  |  |  |
Selling, general and administrative | 4,704 |  |  | 5,048 |  |  |  |  |
Research, development and engineering | 335 |  |  | 380 |  |  |  |  |
Restructuring and other charges | 215 |  |  | 29 |  |  |  |  |
Total stock-based compensation expense | $ | 6,662 |  |  | $ | 6,880 |  |  |  |  |

Modification of Awards
On April 21, 2025, the Board approved a planned leadership succession under which Joseph W. Dziedzic, the Company’s then President and Chief Executive Officer, continued in that role through October 24, 2025, transitioned to a non‑executive special advisor role, and separated from the Company on March 31, 2026. In connection with his separation, and pursuant to an executive retirement agreement dated April 22, 2025, Mr. Dziedzic received retirement eligibility treatment for his outstanding equity awards in exchange for a release of claims and an extension of post‑termination restrictive covenants.
Effective March 31, 2026, Mr. Dziedzic’s unvested time‑based restricted stock units (“RSUs”) vested in full, and his outstanding performance‑based restricted stock units (“PRSUs”) vested on a prorated basis in accordance with the applicable award agreements. The PRSUs remain subject to achievement of the applicable performance conditions and will be paid, if earned, pursuant to the original award terms. Absent this modification, all unvested RSUs and PRSUs would have been forfeited upon separation.
- 15 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(7.) STOCK-BASED COMPENSATION (Continued)
The modification was accounted for under ASC 718. On March 31, 2026, the Company reversed previously recognized compensation expense and recognized compensation cost based on the fair value of the modified awards, as follows:
•RSUs: 15,333 unvested RSUs vested immediately, resulting in compensation cost of $1.3 million based on a fair value of $88.00 per share. Previously recognized expense of $0.3 million was reversed, and $1.3 million was recognized on March 31, 2026.
•PRSUs—financial performance conditions: The prorated outstanding awards totaled 18,573 PRSUs, with a fair value of $1.6 million based on a share price of $88.00. Previously recognized expense of $2.1 million was reversed, and $1.6 million was recognized on March 31, 2026. These awards are no longer subject to a service requirement but remain subject to financial performance conditions.
•PRSUs—market‑based performance conditions: The prorated outstanding awards totaled 16,292 PRSUs, with a fair value of $1.4 million determined using a Monte Carlo valuation model. Previously recognized expense of $2.1 million was reversed, and $1.4 million was recognized on March 31, 2026. These awards are no longer subject to a service requirement but remain subject to market‑based performance conditions.
The incremental impact of the modification was recognized within stock‑based compensation expense during the three months ended March 31, 2026.
Stock Options
The following table summarizes the Company’s stock option activity for the three month period ended April 3, 2026:

| Number of Stock Options |  | Weighted Average Exercise Price |  | Weighted Average Remaining Contractual Life (In Years) |  | Aggregate Intrinsic Value (In Millions)
Outstanding at December 31, 2025 | 20,229 |  |  | $ | 37.48 |  |  |  |  |
Exercised | (2,883) |  |  | 48.43 |  |  |  |  |
Outstanding and exercisable at April 3, 2026 | 17,346 |  |  | $ | 35.66 |  |  | 1.1 |  | $ | 0.9 |

Time-Based Restricted Stock Units
Most RSUs granted to employees during the three months ended April 3, 2026 vest over a period of three years from the grant date, subject to the recipient’s continuous service to the Company. RSUs are issued to non-employee members of the Board as a portion of their annual retainer and vest quarterly over a period of one year. Non-employee directors that take office other than on the date of an annual meeting receive a prorated portion of the annual equity retainer, as of the date he or she takes office. Any prorated annual equity retainer will vest in equal installments on each regularly scheduled vesting date applicable to non-employee directors who have continuously served since the most recent annual meeting. The grant-date fair value of all RSUs is equal to the closing market price of Integer common stock on the date of grant.
The following table summarizes RSU activity for the three month period ended April 3, 2026:

| Time-Vested Activity |  | Weighted Average Grant Date Fair Value
Nonvested at December 31, 2025 | 296,384 |  |  | $ | 107.27 |
Granted | 154,824 |  |  | 85.78 |
Vested | (164,059) |  |  | 98.53 |
Forfeited | (7,288) |  |  | 106.45 |
Nonvested at April 3, 2026 | 279,861 |  |  | $ | 100.52 |

- 16 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(7.) STOCK-BASED COMPENSATION (Continued)
Performance-Based Restricted Stock Units
For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned (0% to 200% of the target award) depends on the achievement of financial and market-based performance conditions. The financial performance conditions are based on the Company’s sales targets over a three year performance period. The market-based performance conditions are based on the Company’s achievement of a relative total shareholder return performance requirement, on a percentile basis, compared to a defined group of peer companies over a three year performance period.
The following table summarizes PRSU activity for the three month period ended April 3, 2026:

| Performance- Vested Activity |  | Weighted Average Grant Date Fair Value
Nonvested at December 31, 2025 | 215,385 |  |  | $ | 109.23 |
Granted | 94,524 |  |  | 91.17 |
Performance adjustment(a) | 66,924 |  |  | 74.34 |
Vested | (146,201) |  |  | 74.34 |
Forfeited | (24,790) |  |  | 185.47 |
Nonvested at April 3, 2026 | 205,842 |  |  | $ | 105.19 |

__________
(a)Represents additional PRSUs earned related to above-target achievement of performance conditions, the achievement of which was based upon predefined performance targets established by the Compensation Committee at the initial grant date.
The Company uses a Monte Carlo simulation model to determine the grant-date fair value of awards with market-based performance conditions. The grant-date fair value of all other PRSUs is equal to the closing market price of the Common Stock on the date of grant. The weighted average fair value and assumptions used to value the PRSU awards granted with market-based performance conditions are as follows:

| Three Months Ended
| April 3, 2026 |  | March 28, 2025
Weighted average fair value | $ | 97.28 |  |  | $ | 162.62 |
Risk-free interest rate | 3.64 | % |  | 4.29 | %
Expected volatility | 37 | % |  | 33 | %
Expected life (in years) | 3.0 |  | 3.0
Expected dividend yield | — | % |  | — | %

The valuation of the market-based PRSUs granted during 2026 and 2025 also reflects a weighted average illiquidity discount of 10.98% and 8.78%, respectively, related to a period of up to one-year that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting.
- 17 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(8.) RESTRUCTURING AND OTHER CHARGES
Restructuring and other charges comprise the following (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Restructuring charges | $ | 607 |  |  | $ | 664 |  |  |  |  |
Acquisition and integration costs | 1,442 |  |  | 4,742 |  |  |  |  |
Other general expenses | 723 |  |  | (1) |  |  |  |  |
Total restructuring and other charges | $ | 2,772 |  |  | $ | 5,405 |  |  |  |  |

Restructuring programs
Operational excellence
The Company’s operational excellence initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes.
Strategic reorganization and alignment
The Company’s strategic reorganization and alignment initiatives primarily include those that align resources with market conditions and the Company’s strategic direction in order to enhance the profitability of its portfolio of products.
Manufacturing alignment to support growth
The Company’s manufacturing alignment to support growth initiatives are designed to reduce costs, improve operating efficiencies or increase capacity to accommodate growth, which may involve relocation or consolidation of manufacturing operations.
The following table comprises restructuring and restructuring-related charges (gains) by classification in the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Restructuring charges: |  |  |  |  |  |  |
Restructuring and other charges | $ | 607 |  |  | $ | 664 |  |  |  |  |
Restructuring-related expenses(a): |  |  |  |  |  |  |
Cost of sales | 1,002 |  |  | 401 |  |  |  |  |
Selling, general and administrative | 85 |  |  | 43 |  |  |  |  |
Research, development and engineering | 154 |  |  | (6) |  |  |  |  |
Total restructuring and restructuring-related charges | $ | 1,848 |  |  | $ | 1,102 |  |  |  |  |

__________
(a) Restructuring-related expenses primarily include retention bonuses, consulting expenses, professional fees and equipment relocation costs.
- 18 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(8.) RESTRUCTURING AND OTHER CHARGES (Continued)
The following table summarizes the activity for restructuring reserves (in thousands):

| Operational excellence |  | Strategic reorganization and alignment |  | Manufacturing alignment to support growth |  | Total
December 31, 2025 | $ | 122 |  |  | $ | 10 |  |  | $ | 27 |  |  | $ | 159 |
Charges incurred, net of reversals | 391 |  |  | — |  |  | 216 |  |  | 607 |
Non-cash charges incurred (included above) | (214) |  |  | — |  |  | — |  |  | (214) |
Cash payments | (134) |  |  | (4) |  |  | (219) |  |  | (357) |
April 3, 2026 | $ | 165 |  |  | $ | 6 |  |  | $ | 24 |  |  | $ | 195 |

Acquisition and integration costs
Acquisition and integration costs primarily consist of professional fees directly related to completed and contemplated business acquisitions and costs to integrate the systems, processes and organizations acquired. During the three months ended April 3, 2026, acquisition and integration costs included $0.7 million related to an investment in a convertible debt instrument. See Note 13, “Financial Instruments and Fair Value Measurements,” for additional information related to the convertible debt instrument.
Acquisition and integration costs comprise the following (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Acquisition costs | $ | 973 |  |  | $ | 2,844 |  |  |  |  |
Integration costs | 469 |  |  | 1,898 |  |  |  |  |
Acquisition and integration costs | $ | 1,442 |  |  | $ | 4,742 |  |  |  |  |

Other general expenses
During the three months ended April 3, 2026 and March 28, 2025, the Company recorded expenses related to other initiatives not described above, which primarily include gains and losses in connection with the disposal of property, plant and equipment.
- 19 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(9.) INCOME TAXES
The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. In addition, the Company continues to explore tax planning opportunities that may have a material impact on its effective tax rate.

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Income (loss) from continuing operations before taxes | $ | 20,351 |  |  | $ | (12,999) |  |  |  |  |
Provision for income taxes | 3,845 |  |  | 9,466 |  |  |  |  |
Effective tax rate | 18.9 | % |  | (72.8) | % |  |  |  |

The difference between the Company’s effective tax rates and the U.S. federal statutory income tax rate of 21% for the first quarter of 2026 is due principally to the net impact of the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S. federal rate, the Net CFC Tested Income (“NCTI”), (formerly Global Intangible Low-Taxed Income (“GILTI”) tax), the Foreign Derived Deduction Eligible Income (“FDDEI”), (formerly, Foreign Derived Intangible Income (“FDII”) deduction), the availability of tax credits and the recognition of certain discrete tax items. The difference between the Company’s effective tax rates and the U.S. federal statutory income tax rate of 21% for the first quarter of 2025 is due principally to the impact of the Convertible Notes Exchange Transactions, including the nondeductible induced conversion expense and reduction of future original issue discount amortization for U.S. income tax purposes. To a lesser extent, the remaining difference between the Company’s effective tax rate and the U.S. federal statutory income tax rate for the first quarter of 2025 is consistent with the differences recognized in the first quarter of 2026.
For the first quarter of 2026, the Company recorded discrete tax expense of $0.1 million, compared to a discrete tax benefit of $1.5 million for the first quarter of 2025. The discrete tax expense for the first quarter of 2026 relates predominantly to shortfalls recognized upon the vesting of RSUs and the discrete tax benefits for the first quarter 2025 are predominately related to excess tax benefits, net of deductibility limitations, recognized upon vesting of RSUs.
Unrecognized tax benefits reflect the difference between positions taken or expected to be taken on income tax returns and the amounts reflected in the financial statements. As of April 3, 2026, the Company had unrecognized tax benefits of approximately $2.9 million, substantially all of which would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.
For a description of the Company’s significant tax matters, reference is made to the financial statements as of and for the year ended December 31, 2025 and Note 13 thereto included in the Company’s 2025 Annual Report.
- 20 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(10.) COMMITMENTS AND CONTINGENCIES
Contingent Consideration Arrangements
The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 13, “Financial Instruments and Fair Value Measurements” for additional information.
Litigation
On December 10, 2025, a putative class action lawsuit was filed in the United States District Court for the Southern District of New York against Integer and certain of its executives, captioned West Palm Beach Firefighters’ Pension Fund v. Integer Holdings Corporation, et al. (the “Securities Action”). In March 2026, the court appointed Pembroke Pines Pension Fund for Firefighters and Police Officers as lead plaintiff and recaptioned the case as Pembroke Pines Pension Fund for Firefighters and Police Officers v. Integer Holdings Corporation. An amended complaint was subsequently filed on April 10, 2026. The amended complaint in the lawsuit alleges violations of the securities laws in the company’s public disclosures. The amended complaint seeks monetary damages, costs and attorney’s fees, and other unspecified relief. Defendants’ deadline to file a motion to dismiss the amended complaint is May 1, 2026. Integer denies any wrongdoing and intends to vigorously defend itself against the claims in the Securities Action.
In addition, the Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future.
- 21 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(11.) EARNINGS PER SHARE (“EPS”)
The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Numerator for basic and diluted EPS: |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 16,506 |  |  | $ | (22,465) |  |  |  |  |
Loss from discontinued operations | — |  |  | (22) |  |  |  |  |
Net income (loss) | $ | 16,506 |  |  | $ | (22,487) |  |  |  |  |
Denominator for basic and diluted EPS: |  |  |  |  |  |  |
Weighted average shares outstanding - Basic | 34,278 |  |  | 33,916 |  |  |  |  |
Dilutive effect of share-based awards | 155 |  |  | — |  |  |  |  |
Weighted average shares outstanding - Diluted | 34,433 |  |  | 33,916 |  |  |  |  |
Basic earnings (loss) per share: |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 0.48 |  |  | $ | (0.66) |  |  |  |  |
Loss from discontinued operations | — |  |  | — |  |  |  |  |
Basic earnings (loss) per share | $ | 0.48 |  |  | $ | (0.66) |  |  |  |  |
Diluted earnings (loss) per share: |  |  |  |  |  |  |
Income (loss) from continuing operations | $ | 0.48 |  |  | $ | (0.66) |  |  |  |  |
Loss from discontinued operations | $ | — |  |  | $ | — |  |  |  |  |
Diluted earnings (loss) per share | $ | 0.48 |  |  | $ | (0.66) |  |  |  |  |

For periods in which the Company has reported a loss from continuing operations, diluted earnings (loss) per share is the same as basic earnings (loss) per share, as the effects of common stock equivalents outstanding and shares issuable upon conversion of convertible debt instruments are antidilutive and, therefore, excluded from the calculation of diluted earnings (loss) per share.
During the three months ended April 3, 2026, the potential conversion of the Convertible Notes was not included in the diluted earnings per share calculation because the average closing price of the Company's common stock for the period, which is used as the basis for determining the dilutive effect on earnings per share, was less than the applicable conversion price.
The following table sets forth potential shares of Common Stock that are not included in the diluted earnings per share calculation above because to do so would be anti-dilutive for the periods indicated (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Stock options and RSUs | 80 |  |  | 432 |  |  |  |  |
PRSUs | 84 |  |  | 226 |  |  |  |  |
Common Stock issuable upon conversion of the 2028 Notes | — |  |  | 1,649 |  |  |  |  |

- 22 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(12.) STOCKHOLDERS’ EQUITY
Common Stock
The following is a summary of the number of shares of Common Stock issued and outstanding for the three month periods ended April 3, 2026 and March 28, 2025:

| Issued |  | Treasury Stock |  | Outstanding
Beginning balance at December 31, 2025 | 35,481,805 |  |  | (1,135,355) |  |  | 34,346,450 |
Stock options exercised | — |  |  | 1,084 |  |  | 1,084 |
Vested and settled RSUs and PRSUs, net of shares withheld to cover taxes | — |  |  | 187,611 |  |  | 187,611 |
Repurchases of common stock | — |  |  | (589,605) |  |  | (589,605) |
Ending balance at April 3, 2026 | 35,481,805 |  |  | (1,536,265) |  |  | 33,945,540 |
Beginning balance at December 31, 2024 | 33,546,262 |  |  | (6) |  |  | 33,546,256 |
Stock options exercised | 3,796 |  |  | — |  |  | 3,796 |
Vested and settled RSUs and PRSUs, net of shares withheld to cover taxes | 190,588 |  |  | — |  |  | 190,588 |
Stock issued upon conversion of convertible debt | 1,553,806 |  |  | — |  |  | 1,553,806 |
Exercise of capped call upon conversion of convertible debt | — |  |  | (436,963) |  |  | (436,963) |
Stock issued for acquisition | 32,393 |  |  | — |  |  | 32,393 |
Ending balance at March 28, 2025 | 35,326,845 |  |  | (436,969) |  |  | 34,889,876 |

Share Repurchase Program
On November 4, 2025, the Company announced that the Board had approved a share repurchase program whereby the Company may, from time to time, repurchase on the open market, in privately-negotiated purchases, including accelerated repurchases, or otherwise, up to $200.0 million of its common stock (the “Share Repurchase Program”). The Share Repurchase Program has no expiration date and will continue until otherwise suspended or terminated. The Share Repurchase Program does not obligate the Company to repurchase any dollar amount or number of shares and may be executed at the discretion of management on an opportunistic basis, or pursuant to trading plans or other arrangements. Shares of our common stock repurchased under the Share Repurchase Program are classified as treasury stock and recorded at cost on the Consolidated Balance Sheets.
On February 19, 2026, the Company entered into an accelerated share repurchase agreement (“ASR Agreement”) with Bank of America, N.A. ("Bank of America") to repurchase approximately $50.0 million of common stock under the Share Repurchase Program. Under the terms of the ASR Agreement, the Company paid Bank of America $50.0 million on February 19, 2026 and on that date received initial delivery of 462,535 shares, representing approximately 80% of the shares to be repurchased over the course of the ASR Agreement. On April 2, 2026, Bank of America delivered 127,070 additional shares which completed the ASR Agreement totaling 589,605 repurchased shares. The total number of shares ultimately repurchased under the ASR Agreement was based on the volume-weighted average price of the Company’s Common Stock during the repurchase period under the ASR Agreement, less a discount, which was $84.80 over the term of the ASR Agreement. The Company used available cash and borrowings under our credit facility to fund the repurchase of the common shares under the ASR Agreement. As of April 3, 2026, the Company had $100 million of capacity remaining under the Share Repurchase Program.
- 23 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(12.) STOCKHOLDERS’ EQUITY (Continued)
Accumulated Other Comprehensive Income
Accumulated other comprehensive income (“AOCI”) comprises the following (in thousands):

| Defined Benefit Plan Liability |  | Cash Flow Hedges |  | Foreign Currency Translation Adjustment |  | Total Pre-Tax Amount |  | Tax |  | Net-of-Tax Amount
December 31, 2025 | $ | (113) |  |  | $ | 5,221 |  |  | $ | 54,144 |  |  | $ | 59,252 |  |  | $ | (1,050) |  |  | $ | 58,202 |
Unrealized loss on cash flow hedges | — |  |  | (6,595) |  |  | — |  |  | (6,595) |  |  | 1,385 |  |  | (5,210) |
Realized loss on foreign currency hedges | — |  |  | 2,935 |  |  | — |  |  | 2,935 |  |  | (616) |  |  | 2,319 |
Foreign currency translation loss | — |  |  | — |  |  | (10,654) |  |  | (10,654) |  |  | — |  |  | (10,654) |
April 3, 2026 | $ | (113) |  |  | $ | 1,561 |  |  | $ | 43,490 |  |  | $ | 44,938 |  |  | $ | (281) |  |  | $ | 44,657 |

December 31, 2024 | $ | 67 |  |  | $ | (6,482) |  |  | $ | (8,985) |  |  | $ | (15,400) |  |  | $ | 1,357 |  |  | $ | (14,043) |
Unrealized gain on cash flow hedges | — |  |  | 4,400 |  |  | — |  |  | 4,400 |  |  | (923) |  |  | 3,477 |
Realized loss on foreign currency hedges | — |  |  | 1,293 |  |  | — |  |  | 1,293 |  |  | (272) |  |  | 1,021 |
Foreign currency translation gain | — |  |  | — |  |  | 20,291 |  |  | 20,291 |  |  | — |  |  | 20,291 |
March 28, 2025 | $ | 67 |  |  | $ | (789) |  |  | $ | 11,306 |  |  | $ | 10,584 |  |  | $ | 162 |  |  | $ | 10,746 |

(13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.
The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and may use derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the Condensed Consolidated Balance Sheets.
The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands):

| Fair Value |  | Quoted Prices in Active Markets (Level 1) |  | Significant Other Observable Inputs (Level 2) |  | Significant Unobservable Inputs (Level 3)
April 3, 2026 |  |  |  |  |  |  |
Assets: Foreign currency hedging contracts | $ | 3,480 |  |  | $ | — |  |  | $ | 3,480 |  |  | $ | — |
Liabilities: Foreign currency hedging contracts | 1,919 |  |  | — |  |  | 1,919 |  |  | — |
Liabilities: Contingent consideration | 8,179 |  |  | — |  |  | — |  |  | 8,179 |
December 31, 2025 |  |  |  |  |  |  |
Liabilities: Foreign currency hedging contracts | $ | 5,221 |  |  | $ | — |  |  | $ | 5,221 |  |  | $ | — |
Liabilities: Contingent consideration | 8,179 |  |  | — |  |  | — |  |  | 8,179 |

- 24 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Derivatives Designated as Hedging Instruments
Foreign Currency Contracts
The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges.
Information regarding outstanding foreign currency forward contracts as of April 3, 2026 is as follows (dollars in thousands):

Notional Amount |  | Maturity Date |  | $/Foreign Currency |  | Fair Value |  | Balance Sheet Location
$ | 38,320 |  |  | Apr 2027 |  | 0.0507 |  | MXN Peso |  | $ | 3,395 |  |  | Prepaid expenses and other current assets
1,543 |  |  | Oct 2026 |  | 0.2421 |  | MYR Ringgit |  | 42 |  |  | Prepaid expenses and other current assets
1,967 |  |  | Oct 2026 |  | 0.0242 |  | UYU Peso |  | 43 |  |  | Prepaid expenses and other current assets
50,362 |  |  | Dec 2026 |  | 1.1826 |  | Euro |  | (1,012) |  |  | Accrued expenses and other current liabilities
11,215 |  |  | Apr 2027 |  | 0.0564 |  | MXN Peso |  | (325) |  |  | Accrued expenses and other current liabilities
3,680 |  |  | Apr 2027 |  | 0.2588 |  | MYR Ringgit |  | (132) |  |  | Accrued expenses and other current liabilities
11,043 |  |  | Apr 2027 |  | 0.0256 |  | UYU Peso |  | (367) |  |  | Accrued expenses and other current liabilities
3,969 |  |  | Jul 2027 |  | 0.0550 |  | MXN Peso |  | (83) |  |  | Other long-term liabilities

Information regarding outstanding foreign currency forward contracts as of December 31, 2025 is as follows (dollars in thousands):

Notional Amount |  | Maturity Date |  | $/Foreign Currency |  | Fair Value |  | Balance Sheet Location
$ | 15,906 |  |  | Oct 2026 |  | 1.1610 |  | Euro |  | $ | 266 |  |  | Prepaid expenses and other current assets
7,649 |  |  | Oct 2026 |  | 0.0244 |  | UYU Peso |  | 383 |  |  | Prepaid expenses and other current assets
51,699 |  |  | Dec 2026 |  | 0.0501 |  | MXN Peso |  | 4,491 |  |  | Prepaid expenses and other current assets
2,959 |  |  | Oct 2026 |  | 0.2401 |  | MYR Ringgit |  | 82 |  |  | Prepaid expenses and other current assets
3,842 |  |  | Apr 2027 |  | 0.0519 |  | MXN Peso |  | 76 |  |  | Other long-term assets
8,923 |  |  | Jul 2026 |  | 1.1898 |  | Euro |  | (77) |  |  | Accrued expenses and other current liabilities

The following tables present the effect of cash flow hedge derivative instruments on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income for the three and three months ended April 3, 2026 and March 28, 2025 (in thousands):

|  | Three Months Ended
|  | April 3, 2026 |  | March 28, 2025
|  | Total |  | Amount of Gain (Loss) on Cash Flow Hedge Activity |  | Total |  | Amount of Gain (Loss) on Cash Flow Hedge Activity
Sales |  | $ | 439,580 |  |  | $ | (116) |  |  | $ | 437,392 |  |  | $ | (583) |
Cost of sales |  | 329,985 |  |  | (2,819) |  |  | 317,074 |  |  | (693) |
Operating expenses |  | 77,726 |  |  | — |  |  | 70,766 |  |  | (17) |

- 25 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)

|  | Unrealized Gain (Loss) Recognized in OCI |  | Realized Gain (Loss) Reclassified from AOCI
|  | Three Months Ended |  | Location in Statements of Operations and Comprehensive Income |  | Three Months Ended
|  | April 3, 2026 |  | March 28, 2025 |  |  | April 3, 2026 |  | March 28, 2025
Foreign exchange contracts |  | $ | (1,407) |  |  | $ | 1,808 |  |  | Sales |  | $ | (116) |  |  | $ | (583) |
Foreign exchange contracts |  | (5,096) |  |  | 2,419 |  |  | Cost of sales |  | (2,819) |  |  | (693) |
Foreign exchange contracts |  | (92) |  |  | 349 |  |  | Operating expenses |  | — |  |  | (17) |

The Company expects to reclassify net gains totaling $1.6 million related to its cash flow hedges from AOCI into earnings during the next twelve months.
Derivatives Not Designated as Hedging Instruments
The Company also has foreign currency exposure on balances, primarily intercompany, that are denominated in a foreign currency and are adjusted to current values using period-end exchange rates. To minimize foreign currency exposure, the Company enters into foreign currency contracts with a one month maturity. At April 3, 2026 and December 31, 2025, the Company had total notional amounts of $79.5 million and $73.4 million, respectively, of foreign currency contracts outstanding that were not designated as hedges. The fair value of derivatives not designated as hedges was not material for any period presented. Gains/losses on foreign currency contracts not designated as hedging instruments are included in Other loss, net on the Condensed Consolidated Statements of Operations and Comprehensive Income. The Company recorded net gains of $0.1 million for the three months ended April 3, 2026, compared to net gains of $0.6 million for the three months ended March 28, 2025.
Contingent Consideration
The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the three and three months ended April 3, 2026 and March 28, 2025 (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Fair value measurement at beginning of period | $ | 8,179 |  |  | $ | 904 |  |  |  |  |
Amount recorded for current year acquisitions | — |  |  | 2,541 |  |  |  |  |
Fair value measurement at end of period | $ | 8,179 |  |  | $ | 3,445 |  |  |  |  |

As of April 3, 2026 and December 31, 2025, the current and non-current portions of the contingent consideration liability were $7.0 million and $1.2 million, respectively. Any current portion of contingent consideration is included in Accrued expenses and other current liabilities and any non-current portion is included in Other long-term liabilities on the Condensed Consolidated Balance Sheets.
The Company will make earnout payments in 2026 of up to $7.0 million based on the achievement of specified milestones being met in 2026. The significant unobservable inputs used to calculate the fair value of the contingent consideration for all acquisitions other than Biocoat are projected revenue for the remaining earnout periods. The payment related to the Biocoat acquisition is contingent upon specified operational milestones being met after close. Actual results will differ from the projected results and could have a significant impact on the estimated fair value of the contingent considerations.
- 26 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
The following table provides information on unpaid contingent consideration as of April 3, 2026 (in thousands):

|  |  |  |  |  | As of April 3, 2026
|  |  |  |  |  | Maximum Remaining Payout (undiscounted) |  |
Acquisition |  | Acquisition Date |  | RemainingMilestone Years |  | 2026 |  | 2027 |  | 2028 |  | 2029 |  | Total |  | Fair Value
Biocoat |  | 12/04/25 |  | 2026 |  | $ | 7,000 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 7,000 |  |  | $ | 7,000 |
VSi |  | 02/28/25 |  | 2026 - 2028 |  | — |  |  | 1,000 |  |  | 1,000 |  |  | 1,000 |  |  | 3,000 |  |  | 1,179 |
InNeuroCo |  | 10/01/23 |  | 2026 - 2027 |  | — |  |  | 2,700 |  |  | 2,700 |  |  | — |  |  | 5,400 |  |  | — |

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis
Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items.
Borrowings under the Company’s Revolving Credit Facility and TLA Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments.
Equity and Other Investments
The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Condensed Consolidated Balance Sheets.
Equity and other investments comprise the following (in thousands):

|  |  |  |  | April 3, 2026 |  | December 31, 2025
Equity method investment |  |  |  |  | $ | 6,197 |  |  | $ | 7,709 |
Non-marketable equity securities |  |  |  |  | 180 |  |  | 180 |
Convertible debt instrument |  |  |  |  | 13,849 |  |  | — |
Total equity and other investments |  |  |  |  | $ | 20,226 |  |  | $ | 7,889 |

During the first quarter of 2026, the Company invested 12 million euro ($13.8 million) in a convertible debt instrument issued by a life sciences company that matures on December 31, 2035. The instrument has a stated interest of 4.55%, payable periodically during the term of the instrument. Depending on certain operational and financial targets, the Company may invest an additional 3 million euro under the same terms. The instrument is senior to all other indebtedness, and is secured by the assets of the investee. The Company considered guidance within ASC 815 and concluded the conversion option did not require bifurcation as an embedded derivative instrument.
The components of (Gain) loss on equity investments for each period were as follows (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Equity method investment (gain) loss | $ | 1,468 |  |  | $ | (181) |  |  |  |  |

The Company’s equity method investment is in a venture capital fund focused on investing in life sciences companies. As of April 3, 2026, the Company owned 8.0% of this fund.
- 27 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(14.) SEGMENTS AND DISAGGREGATED REVENUE
The Company operates as one operating segment. The Company's chief operating decision maker ("CODM") is its Chief Executive Officer, who reviews financial information presented on a consolidated basis. The CODM uses consolidated income from continuing operations to make key operating decisions, including resource allocations and performance assessments. Refer to the Condensed Consolidated Statement of Operations and Comprehensive Income for financial results of the Company’s operating segment.
The following table presents Property, Plant and Equipment (“PP&E”) by geographic area. In these tables, PP&E is aggregated based on the physical location of the tangible long-lived assets (in thousands):

| April 3, 2026 |  | December 31, 2025
Long-lived tangible assets by geographic area: |  |  |
United States | $ | 296,830 |  |  | $ | 297,441 |
Ireland | 155,951 |  |  | 160,511 |
Mexico | 47,232 |  |  | 45,922 |
Rest of world | 33,131 |  |  | 32,553 |
Total | $ | 533,144 |  |  | $ | 536,427 |

The following table presents sales by product line (in thousands):

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Cardio & Vascular | $ | 261,733 |  |  | $ | 258,871 |  |  |  |  |
Cardiac Rhythm Management & Neuromodulation | 168,264 |  |  | 160,345 |  |  |  |  |
Other Markets | 9,583 |  |  | 18,176 |  |  |  |  |
Total sales | $ | 439,580 |  |  | $ | 437,392 |  |  |  |  |

Revenue recognized from products and services transferred to customers over time represented 38% and 33% of total revenue for the three months ended April 3, 2026 and March 28, 2025, respectively.
The following tables present revenues by significant customers, which are defined as any customer who individually represents 10% or more of total revenues.

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
Customer A | 19% |  | 14% |  |  |  |
Customer B | 18% |  | 15% |  |  |  |
Customer C | 15% |  | 21% |  |  |  |
All other customers | 48% |  | 50% |  |  |  |

The following tables present revenues by significant ship to location, which is defined as any country where 10% or more of total revenues are shipped.

| Three Months Ended |  |
| April 3, 2026 |  | March 28, 2025 |  |  |  |
United States | 53% |  | 52% |  |  |  |
Costa Rica | 13% |  | * |  |  |  |
All other countries | 34% |  | 48% |  |  |  |

- 28 -

Table of Contents
INTEGER HOLDINGS CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(14.) SEGMENTS AND DISAGGREGATED REVENUE (Continued)
Contract Balances
The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands):

| April 3, 2026 |  | December 31, 2025
Contract assets | $ | 115,727 |  |  | $ | 112,546 |
Contract liabilities (included in Accrued expenses and other current liabilities) | 5,383 |  |  | 5,213 |
Contract liabilities (included in Other long-term liabilities) | 3,032 |  |  | 3,265 |

During the three months ended April 3, 2026, the Company recognized $1.1 million of revenue that was included in the contract liability balance as of December 31, 2025. During the three months ended March 28, 2025, the Company recognized $1.2 million of revenue that was included in the contract liability balance as of December 31, 2024.
- 29 -

Table of Contents
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10-Q should be read in conjunction with the disclosures included in our Annual Report on Form 10-K for the year ended December 31, 2025. In addition, please read this section in conjunction with our Condensed Consolidated Financial Statements and Notes to Condensed Consolidated Financial Statements contained herein.
Cautionary Note Regarding Forward-Looking Statements
Some statements contained in this report and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to:
•supply chain pressures on the Company and our business;
•future development and expected growth of our business and industry;
•the success of our acquisition strategy;
•our ability to develop new innovative products;
•our ability to execute our business model and our business strategy;
•the outcome of a strategic review process;
•the pipeline of opportunities we intend to pursue in our markets, as well as the timing of launch and value of new products;
•having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and
•projected contractual debt service obligations.
You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are no guarantee of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and to others contained throughout this report. We disclaim any obligation to publicly update or revise the forward-looking statements made in this report as a result of new information, future events or otherwise, except as required by law.
- 30 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
While it is not possible to create a comprehensive list of all factors that may cause actual results to differ from results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include, but in no way are limited to, the following:
•operational risks, such as our dependence upon a limited number of customers; reductions, delays or cancellations in demand from any significant customer or group of customers; pricing pressures and contractual pricing restraints we face from customers; our reliance on third-party suppliers for raw materials, key products and subcomponents; the cost of raw materials, products and subcomponent that are incorporated into our products; trade regulations; changes in order forecasts; our ability to predict and meet the demand for our products; interruptions in our manufacturing operations; uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally; our ability to attract, train and retain a sufficient number of qualified associates to maintain and grow our business; the potential for harm to our reputation and competitive advantage caused by quality problems related to our products; our ability to successfully implement a new global enterprise resource planning (“ERP”) solution; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; global climate change and the emphasis on ESG (as defined below) matters by various stakeholders; our dependence upon our senior management team and key technical personnel; and consolidation in the healthcare industry both at a competitor and customer level, resulting in increased competition and pricing pressure;
•strategic risks, such as the intense competition we face and our ability to successfully market our current or new products; our ability to recover the R&D investments made in the development of new products; our customers in-sourcing or dual sourcing production; our ability to respond to changes in technology; our ability to develop new products and expand into new geographic and product markets; and our ability to successfully identify, make and integrate acquisitions to expand and develop our business in accordance with expectations;
•market, financial and indebtedness risks, such as our ability to accurately forecast future performance based on operating results that often fluctuate; the volatility of our stock price; our failure to meet our publicly announced outlook; the ability of our stock purchase program to enhance stockholder value; stockholder activism; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under the credit agreement governing our senior secured credit facilities (“Senior Secured Credit Facilities”); economic and credit market uncertainties that could interrupt our access to capital markets, borrowings or financial transactions; the conditional conversion feature of the 2028 Notes (as defined below) and the 2030 Notes (as defined below) adversely impacting our liquidity; the conversion of our 2028 Notes and 2030 Notes; diluting ownership interests of existing holders of our common stock; the counterparty risk associated with our capped call transaction; the counter financial and market risks related to our international operations and sales; our complex international tax profile; and our ability to realize the full value of our intangible assets;
•legal and compliance risks, such as legal proceedings against us; regulatory issues resulting from product complaints, recalls or regulatory audits; the potential of becoming subject to product liability or intellectual property claims; our ability to protect our intellectual property and proprietary rights; our ability to comply with customer-driven policies and third-party standards or certification requirements; our ability to obtain and/or retain necessary licenses from third parties for new technologies; our ability and the cost to comply with environmental regulations; legal and regulatory risks from our international operations; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; and our business being indirectly subject to healthcare industry cost containment measures and third-party coverage and reimbursement policies that could result in reduced sales of our products; and
•other risks and uncertainties that arise from time to time.
Unless otherwise noted, any forward-looking statement made by us in this Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. Except as may be required by applicable law, we disclaim any obligation to update forward-looking statements in this Form 10-Q whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.
In this Form 10-Q, references to “Integer,” “we,” “us,” “our” and the “Company” mean Integer Holdings Corporation and its subsidiaries, unless the context indicates otherwise.
- 31 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Our Business
Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation.
We operate our business in one segment and derive our revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets.
The first quarters of 2026 and 2025 ended on April 3, 2026 and March 28, 2025, respectively, and consisted of 93 days and 87 days, respectively.
Impact of Global Events
Our future results of operations and liquidity could be materially adversely affected by uncertainty surrounding macroeconomic and geopolitical factors in the U.S. and globally characterized by the supply chain environment, inflationary pressure, changes in interest rates, disruptions in the commodities’ markets or in supply chain as a result of wars in Ukraine and the Middle East, and the tensions in Asia relating to China and Taiwan, and the introduction of or changes in tariffs or trade barriers. The impact of these issues on our business will vary by geographic market and product line, but specific impacts to our business may include increased borrowing costs, labor shortages, disruptions in the supply chain, delayed or reduced customer orders and sales, delays in shipments to and from certain countries and potential increased expenses resulting from tariffs or other trade barriers.
We monitor economic conditions closely. In response to reductions in revenue, we can take actions to align our cost structure with changes in demand and manage our working capital. However, there can be no assurance as to the effectiveness of our efforts to mitigate any impact of the current and future adverse economic conditions and other developments.
Sales Outlook
In 2026, we expect year over year sales growth to be primarily impacted by lower sales related to three new products due to lower than anticipated market adoption. We believe the magnitude of these changes on multiple products at the same time is highly unusual.
Strategic Review
In April 2026, we announced that the Board had initiated a strategic review to maximize stockholder value. We are considering a full range of potential opportunities including, but not limited to, a sale, merger, or strategic business combination as compared to the value creation opportunities from continued execution of the Company’s standalone strategy. There is no deadline or definitive timeline set for the completion of the strategic review, and there can be no assurance that the review will result in any transaction or other outcome.
Business Acquisitions
We selectively evaluate acquisitions as a means to acquire additional technology or manufacturing capabilities to expand our product offering in our key existing growth markets. Consistent with our tuck-in acquisition strategy, since the beginning of 2022 we have completed the following acquisitions, including those that impact the comparability of our results between periods:
On December 4, 2025, we acquired certain assets of Biocoat. Prior to the acquisition, Biocoat was a privately-held manufacturer specializing in high value surface coating technology platforms, including UV and thermal cure hydrophilic coatings.
On February 28, 2025, we acquired substantially all of the assets and assumed certain liabilities of VSi. Prior to the acquisition, VSi was a privately-held full-service provider of parylene coating solutions, primarily focused on complex medical device applications.
On January 7, 2025, we acquired substantially all of the assets and assumed certain liabilities of Precision. Prior to the acquisition, Precision was a privately-held manufacturer specializing in high value surface coating technology platforms, including fluoropolymer, anodic coatings, ion treatment solutions and laser processing.
Refer to Note 2, “Business Acquisitions” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about the transactions above.
- 32 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Financial Overview
Income (loss) from continuing operations for the first quarter of 2026 was income of $16.5 million, or $0.48 per diluted share, compared to a loss of $22.5 million, or $0.66 per diluted share, for the first quarter of 2025. These variances are primarily the result of the following:
•Sales for the first quarter of 2026 increased $2.2 million when compared to the same period in 2025, driven by higher Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation sales, partially offset by lower Other Markets.
•Gross profit for the first quarter of 2026 decreased $10.7 million, primarily by driven by lower fixed cost absorption due to lower production volumes.
•Operating expenses for the first quarter of 2026 increased $7.0 million when compared to the same period in 2025, primarily due to higher SG&A and RD&E costs, partially offset by and Restructuring and other charges. Operating expenses as a percentage of sales improved to 17.7% for the first quarter of 2026 compared to 16.2% or the first quarter of 2025.
•Interest expense for the first quarter of 2026 decreased $5.1 million compared to the same period in 2025, primarily due to lower interest rates on our outstanding borrowings.
•During the first quarters of 2026 and 2025, we recognized losses on equity investments of $1.5 million compared to gains of $0.2 million, respectively. Gains and losses on equity investments are generally unpredictable in nature.
•Other loss, net for the first quarter of 2026 was $0.3 million compared to $47.9 million for the first quarter of 2025. The first quarter of 2025 includes $46.7 million of debt conversion inducement expense related to the partial exchange of our outstanding 2028 Notes that was completed during the first quarter of 2025.
•We recorded provisions for income taxes for the first quarters of 2026 and 2025 of $3.8 million and $9.5 million, respectively. The change in income tax expense was primarily due to relative changes in pre-tax income and the impact of discrete tax items.
- 33 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Our Financial Results
The following table presents selected financial information derived from our Condensed Consolidated Financial Statements, contained in Item 1 of this report, for the periods presented (dollars in thousands, except per share).

| Three Months Ended |  |  |  |
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Product Line Sales: |  |  |  |  |  |  |
Cardio & Vascular | $ | 261,733 |  |  | $ | 258,871 |  |  | $ | 2,862 |  |  | 1.1 | %
Cardiac Rhythm Management & Neuromodulation | 168,264 |  |  | 160,345 |  |  | 7,919 |  |  | 4.9 | %
Other Markets | 9,583 |  |  | 18,176 |  |  | (8,593) |  |  | (47.3) | %
Total sales | 439,580 |  |  | 437,392 |  |  | 2,188 |  |  | 0.5 | %
Cost of sales | 329,985 |  |  | 317,074 |  |  | 12,911 |  |  | 4.1 | %
Gross profit | 109,595 |  |  | 120,318 |  |  | (10,723) |  |  | (8.9) | %
Gross profit as a % of sales | 24.9 | % |  | 27.5 | % |  |  |  |
Operating expenses: |  |  |  |  |  |  |
Selling, general and administrative (“SG&A”) | 58,711 |  |  | 51,160 |  |  | 7,551 |  |  | 14.8 | %
SG&A as a % of sales | 13.4 | % |  | 11.7 | % |  |  |  |
Research, development and engineering (“RD&E”) | 16,243 |  |  | 14,201 |  |  | 2,042 |  |  | 14.4 | %
RD&E as a % of sales | 3.7 | % |  | 3.2 | % |  |  |  |
Restructuring and other charges | 2,772 |  |  | 5,405 |  |  | (2,633) |  |  | (48.7) | %
Total operating expenses | 77,726 |  |  | 70,766 |  |  | 6,960 |  |  | 9.8 | %
Operating income | 31,869 |  |  | 49,552 |  |  | (17,683) |  |  | (35.7) | %
Operating expense as a % of sales | 17.7 | % |  | 16.2 | % |  |  |  |
Operating income as a % of sales (“Operating margin”) | 7.2 | % |  | 11.3 | % |  |  |  |
Interest expense | 9,734 |  |  | 14,805 |  |  | (5,071) |  |  | (34.3) | %
(Gain) loss on equity investments | 1,468 |  |  | (181) |  |  | 1,649 |  |  | NM
Other loss, net | 316 |  |  | 47,927 |  |  | (47,611) |  |  | (99.3) | %
Income (loss) from continuing operations before taxes | 20,351 |  |  | (12,999) |  |  | 33,350 |  |  | NM
Provision for income taxes | 3,845 |  |  | 9,466 |  |  | (5,621) |  |  | (59.4) | %
Effective tax rate | 18.9 | % |  | (72.8) | % |  |  |  |
Income (loss) from continuing operations | $ | 16,506 |  |  | $ | (22,465) |  |  | $ | 38,971 |  |  | NM
Income (loss) from continuing operations as a % of sales | 3.8 | % |  | (5.1) | % |  |  |  |
Diluted earnings (loss) per share from continuing operations | $ | 0.48 |  |  | $ | (0.66) |  |  | $ | 1.14 |  |  | NM

NM - Calculated change not meaningful.

- 34 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Product Line Sales

| Three Months Ended
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Cardio & Vascular | $ | 261,733 |  |  | $ | 258,871 |  |  | $ | 2,862 |  |  | 1.1 | %
Cardiac Rhythm Management & Neuromodulation | 168,264 |  |  | 160,345 |  |  | 7,919 |  |  | 4.9 |
Other Markets | 9,583 |  |  | 18,176 |  |  | (8,593) |  |  | (47.3) |
Total sales | $ | 439,580 |  | 439580 | $ | 437,392 |  |  | $ | 2,188 |  |  | 0.5 |

For the first quarter of 2026, Cardio & Vascular (“C&V”) sales increased $2.9 million, or 1%, versus the comparable 2025 period. C&V sales for the first quarter of 2026 included $2.7 million in incremental sales from our 2025 acquisitions. Foreign currency exchange rate fluctuations increased C&V sales for the first quarter of 2026 by $1.2 million in comparison to the 2025 period, primarily due to U.S. dollar fluctuations relative to the Euro.
For the first quarter of 2026, Cardiac Rhythm Management & Neuromodulation (“CRM&N”) sales increased $7.9 million, or 5%, versus the comparable 2025 period, driven by Cardiac Rhythm Management growth, partially offset by lower sales due to a Neuromodulation customer. Foreign currency exchange rate fluctuations did not have a material impact on CRM&N sales during the first quarter of 2026 in comparison to 2025.
Other Markets sales for the first quarter of 2026 decreased $8.6 million, or 47%, versus the comparable 2025 period, driven by execution of the Portable Medical Exit. Foreign currency exchange rate fluctuations did not have a material impact on Other Markets sales during the first quarter of 2026 in comparison to 2025.
Gross Profit

| Three Months Ended
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Gross profit (in thousands) | $ | 109,595 |  |  | $ | 120,318 |  |  | $ | (10,723) |  |  | (8.9) | %
Gross margin | 24.9 | % |  | 27.5 | % |  |  |  |

Gross margin declined in the first quarter of 2026, compared to the same prior year period due to the negative impact of lower fixed cost absorption, partly offset by on-going cost reduction initiatives. Gross margin, or gross profit as a percentage of sales, has been and will continue to be affected by a variety of factors, including the average sales price of our products and services and transaction volume growth. We expect our gross margin to fluctuate over time.
- 35 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
SG&A Expenses
Changes to SG&A expenses from the prior year periods were due to the following (in thousands):

| Three Months Ended
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Compensation and benefits(a) | $ | 29,032 |  |  | $ | 27,563 |  |  | $ | 1,469 |  |  | 5.3 | %
Depreciation and amortization expense(b) | 12,862 |  |  | 11,776 |  |  | 1,086 |  |  | 9.2 |
Professional fees(c) | 7,621 |  |  | 3,340 |  |  | 4,281 |  |  | 128.2 |
Contract services(d) | 5,000 |  |  | 3,979 |  |  | 1,021 |  |  | 25.7 |
Travel and entertainment | 437 |  |  | 1,175 |  |  | (738) |  |  | (62.8) |
Bank fees and charges | 831 |  |  | 832 |  |  | (1) |  |  | (0.1) |
All other SG&A | 2,928 |  |  | 2,495 |  |  | 433 |  |  | 17.4 |
Total SG&A expense | $ | 58,711 |  |  | $ | 51,160 |  |  | $ | 7,551 |  |  | 14.8 |

__________
(a)Compensation and benefits increased primarily due to annual merit increases, acquisitions, leadership transitions, and the execution of our enterprise resource planning system implementation.
(b)Depreciation and amortization expense increased due to amortization of customer list intangible assets related to recent acquisitions.
(c)Professional fees were impacted by advisory fees related to a stockholder activist matter. These activist related costs amounted to $3.2 million for the first quarter of 2026. As a result of the previously disclosed cooperation agreement reached with the activist investor in March 2026, we do not anticipate we will incur any further costs related to this matter.
(d)Contract services expense increased primarily due to higher software costs from information technology enhancements.
RD&E
RD&E expense for the first quarter of 2026 was $16.2 million, compared to $14.2 million for the first quarter 2025. The increase in RD&E expense during 2026 compared to 2025 is primarily due to the timing of program milestone achievements for customer funded programs. RD&E expenses are influenced by the number and timing of in-process projects and labor hours and other costs associated with these projects. Our research and development initiatives continue to emphasize new product development, product improvements, and the development of new technological platform innovations.
- 36 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Restructuring and Other Charges
We continuously evaluate our business and identify opportunities to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs. To realize the benefits associated with these opportunities, we undertake restructuring-type activities to transform our business. We incur costs associated with these activities, which primarily include exit and disposal costs and other costs directly related to the restructuring initiative. Restructuring charges include exit and disposal costs from these activities. In addition, from time to time, we incur costs associated with acquiring and integrating businesses, and certain other general expenses, including asset impairments.
Restructuring and other charges comprise the following (in thousands):

| Three Months Ended
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Restructuring charges(a) | $ | 607 |  |  | $ | 664 |  |  | $ | (57) |  |  | (8.6) | %
Acquisition and integration costs(b) | 1,442 |  |  | 4,742 |  |  | (3,300) |  |  | (69.6) |
Other general expenses(c) | 723 |  |  | (1) |  |  | 724 |  |  | NM
Total restructuring and other charges | $ | 2,772 |  |  | $ | 5,405 |  |  | $ | (2,633) |  |  | (48.7) |

__________
(a)Restructuring charges for the first three months of 2026 and 2025 primarily consist of costs associated with our strategic reorganization and alignment and manufacturing alignment to support growth initiatives.
(b)Amount for the first three months of 2026 primarily includes $0.7 million of costs related to our investment in a convertible debt instrument during the quarter and integration expenses related to our recent acquisitions. Amount for the first three months of 2025 primarily include acquisition expenses related to the Precision and VSi acquisitions.
(c)Amounts include gains and losses in connection with the disposal of property, plant and equipment.
Refer to Note 8, “Restructuring and Other Charges” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information regarding these initiatives.

- 37 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Interest Expense
Information relating to our interest expense is as follows (dollars in thousands):

| Three Months Ended
| April 3, 2026 |  | March 28, 2025 |  | Change
| Amount |  | Rate |  | Amount |  | Rate |  | Amount |  | Rate (bp)
Contractual interest expense | $ | 7,392 |  |  | 2.39 | % |  | $ | 12,485 |  |  | 4.06 | % |  | $ | (5,093) |  |  | (167)
Amortization of deferred debt issuance costs and original issue discount | 1,625 |  |  | 0.54 |  |  | 1,145 |  |  | 0.42 |  |  | 480 |  |  | 12
Losses from extinguishment of debt | — |  |  | — |  |  | 737 |  |  | 0.25 |  |  | (737) |  |  | (25)
Interest expense on borrowings | 9,017 |  |  | 2.93 | % |  | 14,367 |  |  | 4.73 | % |  | (5,350) |  |  | (180)
Other interest expense | 717 |  |  |  |  | 438 |  |  |  |  | 279 |  |  |
Total interest expense | $ | 9,734 |  |  |  |  | $ | 14,805 |  |  |  |  | $ | (5,071) |  |  |

During 2026, contractual interest expense has decreased due to a lower weighted average interest rate, partially offset by a higher average debt balance outstanding. The favorable weighted average interest rate is due to the replacement of some of our higher variable rate debt with lower fixed rate debt through issuance of the 2030 Notes at the end of the first quarter of 2025. The higher average debt balance outstanding is primarily the result of borrowings to fund the 2025 acquisitions and to repurchase common stock.
Other components of interest expense on borrowings include non-cash amortization and write-off (losses from extinguishment of debt) of deferred debt issuance costs and original issue discount. Amortization of deferred debt issuance costs and original issue discount increased during the first quarter of 2026 compared to the same period in 2025 as a result of higher unamortized balances related to new debt. The losses from extinguishment of debt during the first quarter of 2025 were related to prepayments of portions of the TLA Facility, primarily in connection with issuance of our 2030 Notes.
As of April 3, 2026 and December 31, 2025, approximately 88% and 92%, respectively, of our principal amount of debt are fixed rate borrowings.
See Note 6, “Debt,” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information pertaining to our debt.
(Gain) Loss on Equity Investments
(Gain) loss on equity investments for each period were as follows (in thousands):

| Three Months Ended
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Equity method investment (gain) loss | $ | 1,468 |  |  | $ | (181) |  |  | $ | 1,649 |  |  | NM

Equity method investment (gain) loss for both 2026 and 2025 relates to our share of equity method investee gains including unrealized appreciation/depreciation of the underlying interests of the investee. As of April 3, 2026 and December 31, 2025, the carrying value of our equity investments was $6.4 million and $7.9 million, respectively.
See Note 13, “Financial Instruments and Fair Value Measurements” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further details regarding these investments.

- 38 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Other Loss, Net

| Three Months Ended
| April 3, |  | March 28, |  | Change
| 2026 |  | 2025 |  | $ |  | %
Foreign currency transaction (gains) losses, net(a) | $ | 376 |  |  | $ | 1,144 |  |  | $ | (768) |  |  | (67) | %
Debt conversion inducement expense(b) | — |  |  | 46,681 |  |  | (46,681) |  |  | (100) | %
Other gains (losses), net | (60) |  |  | 102 |  |  | (162) |  |  | (159) | %
| $ | 316 |  |  | $ | 47,927 |  |  | $ | (47,611) |  |  | (99) | %

__________
(a)Represents gains/losses from the impact of exchange rates on transactions denominated in foreign currencies. Our foreign currency transaction gains/losses are based primarily on fluctuations of the U.S. dollar relative to the Euro, Mexican peso, Uruguayan peso, Malaysian ringgits, or Dominican peso.
(b)Debt conversion inducement expense was recognized in the first quarter of 2025 related to the partial exchange of our outstanding 2028 Notes.
Provision for Income Taxes

| Three Months Ended |  |
| April 3, |  | March 28, |  | Change |  |  |  |
| 2026 |  | 2025 |  | $ |  | % |  |  |  |
Income (loss) from continuing operations before taxes | $ | 20,351 |  |  | $ | (12,999) |  |  | $ | 33,350 |  |  | NM |  |  |  |
Provision for income taxes | 3,845 |  |  | 9,466 |  |  | (5,621) |  |  | (59) | % |  |  |  |
Effective tax rate | 18.9 | % |  | (72.8) | % |  |  |  |  |  |  |  |

The decrease in the tax provision was primarily due to an increase in R&D tax credits, an increase in tax benefits associated with realized foreign tax credits, and the impact of the non-recurring 2025 expense associated with the net nondeductible induced conversion expenditures incurred as a result of the induced conversion from the exchange of the 2028 Convertible Notes, partially offset by an increase in global minimum tax (Pillar 2).
Our effective tax rate for 2026 differs from the U.S. federal statutory tax rate of 21% due principally to the estimated impact of Federal Tax Credits (including R&D credits and foreign tax credits), and the application of U.S. and foreign international tax rules related to the taxation of global earnings, including Net CFC tested income (“NCTI”), formerly referred to as global intangible low‑tax income (“GILTI”), the deduction associated with foreign‑derived deduction‑eligible income (“FDDEI”), formerly known as foreign‑derived intangible income (“FDII”), and the impact of the OECD’s Pillar Two global minimum tax framework.
NCTI represents income earned by the Company’s controlled foreign corporations that is subject to current U.S. federal income taxation, after consideration of applicable foreign tax credits. NCTI is treated as a period cost and included in the Company’s income tax provision in the period in which the related foreign earnings arise. The amount of NCTI recognized is influenced by the level and mix of foreign earnings, foreign effective tax rates, and the availability of foreign tax credits.
FDDEI provides a deduction that reduces U.S. taxable income generated from certain qualifying foreign sales and services. The benefit recognized from FDDEI depends on the level of qualifying income, overall U.S. taxable income, and statutory limitations.
In addition, our rate is impacted by earnings realized in foreign jurisdictions with statutory rates that are different than the U.S. federal statutory rate. The primary foreign jurisdictions in which we operate and the statutory tax rate for each respective jurisdiction include Switzerland (22%), Mexico (30%), Uruguay (25%), Ireland (12.5%) and Malaysia (24%). Our manufacturing operations in Costa Rica and the Dominican Republic operate under a free trade zone agreement through April 2031 and March 2034, respectively.
In January 2026, the Organization for Economic Cooperation and Development (“OECD”) released administrative guidance recognizing the U.S. minimum tax regime and introducing a “side-by-side” package intended to exempt U.S. parented groups from Pillar 2 minimum taxes imposed by foreign jurisdictions on U.S. earnings. Although full adoption of the guidance is expected to eliminate this exposure with respect to the U.S. jurisdiction, laws to implement the framework have not been enacted in all relevant countries. Accordingly, our financial results reflect the laws enacted and in effect as of April 3, 2026.
- 39 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Changes in the geographic mix of earnings, foreign income tax rates, the availability of tax credits and deductions, business acquisitions, settlements with taxing authorities, and the continued implementation and interpretation of international tax rules, including NCTI, FDDEI, and Pillar Two, may contribute to volatility in the Company’s effective tax rate in future periods. In addition, we continue to explore tax planning opportunities that may have a material impact on our effective tax rate.
Refer to Note 9, “Income Taxes,” to the accompanying Consolidated Condensed Financial Statements for discussion regarding the Company’s significant tax matters.
Liquidity and Capital Resources
Sources of Liquidity

(dollars in thousands) | April 3, 2026 |  | December 31, 2025 |  |
Cash and cash equivalents | $ | 8,115 |  |  | $ | 17,161 |  |  |
Working capital from continuing operations | $ | 568,420 |  |  | $ | 538,056 |  |  |
Current ratio from continuing operations | 3.75 |  |  | 3.32 |  |  |

Cash and cash equivalents at April 3, 2026 decreased by $9.0 million from December 31, 2025. Cash generated by operating activities of $24.7 million and proceeds from net borrowings on our revolving credit facility of $65.0 million were primarily offset by purchases of property, plant and equipment of $24.0 million, $50.0 million of repurchases of common stock, a $14.0 million investment in a convertible debt instrument, and tax withholding payments related to net share settlements of restricted stock unit awards of $9.0 million.
Working capital increased by $30.4 million from December 31, 2025, or $39.4 million excluding the decrease in cash and cash equivalents. The increase in working capital, exclusive of cash and cash equivalents, primarily relates to positive fluctuations in inventory and accrued expenses and other liabilities, which were partially offset by a decrease in accounts receivable from the favorable timing of customer payments.
At April 3, 2026, $5.6 million of our cash and cash equivalents were held by foreign subsidiaries. We intend to limit our distributions from foreign subsidiaries to previously taxed income or current period earnings. If distributions are made utilizing current period earnings, we will record foreign withholding taxes in the period of the distribution.
As of April 3, 2026, our capital structure consisted of $1,251.5 million of debt, net of deferred debt issuance costs and unamortized discounts and 34 million shares of common stock outstanding. As of April 3, 2026, we had access to $729.7 million of borrowing capacity under our Revolving Credit Facility, available for normal course of business and letters of credit, and are authorized to issue up to 100 million shares of common stock and 100 million shares of preferred stock. As of April 3, 2026, our contractual debt service obligations for the remainder of 2026, consisting of interest on our outstanding debt and commitment fees on the unused portion of the Revolving Credit Facility are estimated to be approximately $17 million. Actual principal and interest payments may be higher if, for instance, the applicable interest rates on our Senior Secured Credit Facilities increase, we borrow additional amounts on our Revolving Credit Facility, or we pay principal amounts in excess of the required minimums reflected in the contractual debt service obligations above.
Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months. If our future financing needs increase, we may need to arrange additional debt or equity financing. We continually evaluate and consider various financing alternatives to enhance or supplement our existing financial resources. However, we cannot be assured that we will be able to enter into any such arrangements on acceptable terms or at all.
Credit Facilities and 2028 Notes
As of April 3, 2026, we had Senior Secured Credit Facilities that consist of an $800 million Revolving Credit Facility, with $65 million outstanding principal balance, and a TLA Facility with an outstanding principal balance of $91 million. The Revolving Credit Facility and TLA Facility mature on February 15, 2028. The Senior Secured Credit Facilities include a mandatory prepayment provision customary for similar credit facilities.
- 40 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
The Revolving Credit Facility and TLA Facility contain covenants requiring that we maintain (i) a Total Net Leverage Ratio not to exceed 5.00:1.00, subject to increase in certain circumstances following certain qualified acquisitions and (ii) an interest coverage ratio of at least 2.50:1.00. As of April 3, 2026, we were in compliance with these financial covenants. As of April 3, 2026, our Total Net Leverage Ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 3.0:1.0. For the twelve month period ended April 3, 2026, our interest coverage ratio, calculated in accordance with our Senior Secured Credit Facilities agreement, was approximately 14.4:1.0.
Failure to comply with these financial covenants would result in an event of default as defined under the Revolving Credit Facility and TLA Facility unless waived by the lenders. An event of default may result in the acceleration of our indebtedness. As a result, management believes that compliance with these covenants is material to us.
Convertible Notes
In March 2025, we issued $1.0 billion aggregate principal amount of 2030 Convertible Notes, which mature on March 15, 2030 and bear interest at a fixed rate of 1.875% per annum. The total net proceeds from the issuance of the 2030 Convertible Notes, after deducting initial purchasers' discounts and commissions and debt issuance costs, were approximately $976 million. We used the net proceeds from the issuance of the 2030 Convertible Notes to pay down our Revolving Credit Facility and TLA Facility, exchange a portion of our 2028 Convertible Notes, and to pay the cost of the capped calls related to the issuance of our 2030 Convertible Notes.
In February 2023, we issued $500 million aggregate principal amount of notes. The 2028 Convertible Notes mature on February 15, 2028 and bear interest at a fixed rate of 2.125% per annum. In March 2025, in connection with the issuance of the 2030 Convertible Notes, the Company used part of the net proceeds therefrom to exchange $383.7 million in aggregate principal amount of the 2028 Convertible Notes in privately-negotiated transactions. As of April 3, 2026, the remaining aggregate principal amount of the 2028 Convertible Notes was $116.3 million.
As of December 31, 2025, the conditions allowing holders of the Convertible Notes to convert had not been met. Any determination regarding the convertibility of the Convertible Notes during future periods will be made in accordance with the terms of the indenture governing the Convertible Notes. These obligations are classified as a long-term liability on the Consolidated Balance Sheet at April 3, 2026.
See Note 6, “Debt” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for a further information on the Company’s outstanding debt.
Share Repurchase Program
On November 4, 2025, we announced that our Board of Directors had approved a share repurchase program authorizing us to repurchase up to an aggregate of $200.0 million of our outstanding common stock (the “Share Repurchase Program”). Under the Share Repurchase Program, we may repurchase shares from time to time on the open market, in privately-negotiated purchases or otherwise. The Share Repurchase Program has no expiration date and will continue until otherwise suspended or terminated. We are not obligated to repurchase any dollar amount or to acquire any specific number of shares and repurchases may be executed at the discretion of management on an opportunistic basis, or pursuant to trading plans or other arrangements. During 2025, we repurchased 698,356 shares of our common stock for a total of $50.0 million.
On February 19, 2026, we entered into an accelerated share repurchase agreement to repurchase $50.0 million of common stock under the Share Repurchase Program. Under the terms of the ASR Agreement, we paid Bank of America $50.0 million on February 19, 2026 and on that date received initial delivery of 462,535 shares of common stock. On April 2, 2026, Bank of America delivered 127,070 additional shares which completed the ASR Agreement totaling 589,605 repurchased shares. The Company used available cash and borrowings under our credit facility to fund the repurchase of the common shares under the ASR Agreement. As of April 3, 2026, the Company had $100 million of capacity remaining under the Share Repurchase Program.
Factoring Arrangements
We utilize accounts receivable factoring arrangements with financial institutions to accelerate the timing of cash receipts and enhance our cash position. These arrangements, in all cases, do not contain recourse provisions, which would obligate us in the event of our customers’ failure to pay. During the first three months of 2026 and 2025, we sold, without recourse, $10.1 million and $58.1 million of accounts receivable, respectively. See Note 3, “Supplemental Financial Statement Disclosures” of the Notes to the Condensed Consolidated Financial Statements contained in Item 1 of this report for further information regarding our factoring arrangements.
- 41 -

Table of Contents
INTEGER HOLDINGS CORPORATION
MANAGEMENT'S DISCUSSION AND ANALYSIS
Summary of Cash Flow
The following cash flow summary information includes cash flows related to discontinued operations.

| Three Months Ended |  |
(in thousands) | April 3, 2026 |  | March 28, 2025 |  |
Cash provided by (used in): |  |  |  |  |
Operating activities | $ | 24,695 |  |  | $ | 31,276 |  |  |
Investing activities | (37,901) |  |  | (197,167) |  |  |
Financing activities | 3,830 |  |  | 151,578 |  |  |
Effect of foreign currency exchange rates on cash and cash equivalents | 330 |  |  | (519) |  |  |
Net change in cash and cash equivalents | $ | (9,046) |  |  | $ | (14,832) |  |  |

Operating Activities – During the first three months of 2026, we generated cash from operations of $24.7 million, compared to $31.3 million for the first three months of 2025, as a $7.2 million decrease in net income adjusted for non-cash items such as depreciation and amortization was partially offset by a decrease in cash flow provided by changes in operating assets and liabilities.
Investing Activities – The $159.3 million decrease in net cash used in investing activities was primarily attributable to lower cash paid for acquisitions offset by the purchase of a long-term investment. Investing activities for the first three months of 2025 included net cash paid of $171.8 million for the Precision and VSi acquisitions.
Financing Activities – Net cash provided by financing activities for the first three months of 2026 was $3.8 million compared to $151.6 million provided by financing activities for the first three months of 2025. In the first three months of 2026, net proceeds of $65.0 million were received from net borrowings under our revolving credit facility and were primarily offset by cash payments of $50.0 million for repurchases of common stock and $9.0 million related to stock-based compensation activity. In the first three months of 2025, the Company received net proceeds from the issuance of our 2030 Notes of $977.5 million, which was partially offset by a $71.0 million purchase of capped call options associated with the 2030 Notes, $383.7 million in aggregate principal amount of exchanged 2028 Notes, $230.0 million of principal payments on our TLA Facility, $126.0 million net payments on our Revolving Credit Facility, and $14.1 million related to stock-based compensation activity.
Off-Balance Sheet Arrangements
We do not currently have off balance sheet arrangements that have or are reasonably likely to have a material current or future effect on our Condensed Consolidated Financial Statements.
Impact of Recently Issued Accounting Standards
In the normal course of business, we evaluate all new accounting pronouncements issued by the FASB, SEC, or other authoritative accounting bodies to determine the potential impact they may have on our Condensed Consolidated Financial Statements. See Note 1, “Basis of Presentation” of the Notes to Condensed Consolidated Financial Statements contained in Item 1 of this report for additional information about these recently issued accounting standards and their potential impact on our financial condition or results of operations.
Critical Accounting Policies and Estimates
The preparation of our Condensed Consolidated Financial Statements in accordance with accounting principles generally accepted in the U.S. requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements and accompanying notes. Our estimates, assumptions and judgments are based on historical experience and various other assumptions believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying amount of assets and liabilities that are not readily apparent from other sources. Making estimates, assumptions and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Management believes the estimates, assumptions and judgments employed and resulting balances reported in the Condensed Consolidated Financial Statements are reasonable; however, actual results could differ materially.
There have been no significant changes to the critical accounting policies and estimates as compared to those disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025.
- 42 -

Table of Contents
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There have been no material changes to the Company’s exposure to market risk from the information provided in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
ITEM 4. CONTROLS AND PROCEDURES
a. Evaluation of Disclosure Controls and Procedures
Our management, including the principal executive officer and principal financial officer, evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) related to the recording, processing, summarization and reporting of information in our reports that we file with the Securities and Exchange Commission as of April 3, 2026. These disclosure controls and procedures have been designed to provide reasonable assurance that material information relating to us, including our subsidiaries, is made known to our management, including these officers, by our employees, and that this information is recorded, processed, summarized, evaluated and reported, as applicable, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Based on their evaluation, as of April 3, 2026, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective.
b. Changes in Internal Control Over Financial Reporting
During the Company’s most recent fiscal quarter, there have been no changes in the Company’s internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
- 43 -

Table of Contents
PART II—OTHER INFORMATION
ITEM 1.LEGAL PROCEEDINGS
For information regarding certain legal proceedings pending against us, see Note 10, “Commitments and Contingencies,” of the Notes to Condensed Consolidated Financial Statements contained in Item 1, “Financial Statements,” of this report, which is incorporated herein by reference.
ITEM 1A.RISK FACTORS
Except as set forth below, there have been no material changes to the Company’s risk factors as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
We are conducting a strategic review of our business and opportunities, and we may not be successful in identifying, pursuing or completing any strategic transaction, and any such strategic transaction, if completed, may not result in additional value for our stockholders. Additionally, we cannot ensure that the strategic review process will not have an adverse impact on our business.
In April 2026, we announced that the Board had initiated a strategic review to maximize stockholder value. We are considering a full range of potential opportunities including, but not limited to, a sale, merger, or strategic business combination as compared to the value creation opportunities from continued execution of the Company’s standalone strategy. We expect to devote substantial time and resources to exploring strategic alternatives with the goal of maximizing stockholder value. However, this strategic review process may not result in our identifying or pursuing any transaction. In the event that we pursue any transaction, we cannot be sure that such transaction will be completed on attractive terms or at all. If any such transaction is consummated it may not lead to increased stockholder value or result in other anticipated benefits. Further, any such transaction could have a variety of negative consequences, and we may pursue or implement a course of action or consummate a transaction that yields unexpected results that adversely affect our business and stockholder value. We have not set a timetable for completion of this strategic review process, and our Board of Directors has not approved a definitive course of action.
Additionally, the process of evaluating these strategic options may be costly, time-consuming, complex and disruptive to our business operations, and we expect to incur significant resources and costs related to this evaluation, such as management’s attention and resources, legal and accounting fees and expenses and other related charges. We may also incur additional unanticipated expenses in connection with this process. We expect a considerable portion of these costs to be incurred regardless of whether any such course of action is identified, implemented or consummated.
If we are not successful in identifying or pursuing a strategic alternative, or if our plans are not executed or consummated in a timely manner, we may suffer reputational harm, and the value of our shares may be adversely affected. In addition, speculation regarding any developments related to the review or pursuit of strategic alternatives and perceived uncertainties related to the future of our business could cause the market price of our shares to fluctuate significantly. Any of the foregoing could have a material adverse effect on our business, prospects, liquidity, financial condition, and results of operations.
- 44 -

Table of Contents
ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table presents the repurchases of our common stock during the three months ended April 3, 2026:

Period |  | Total Number of Shares Purchased(a) |  | Average Price Paid per Share(b) |  | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs(a) |  |  |  | Approximate Dollar Value of Shares That May Yet Be Purchased Under The Plans or Programs (in millions)(c)
January 1, 2026 - January 30, 2026 |  | — |  |  | $ | — |  |  | — |  |  |  |  | $ | — |
January 31, 2026 - February 27, 2026 |  | 462,535 |  |  | 84.80 |  |  | 462,535 |  |  |  |  | 110.8
February 28, 2026 - April 3, 2026 |  | 127,070 |  |  | 84.80 |  |  | 127,070 |  |  |  |  | 100.0
Total |  | 589,605 |  |  |  |  | 589,605 |  |  |  |  |

(a) On February 19, 2026, the Company entered into an accelerated share repurchase agreement (“ASR Agreement”) with Bank of America, N.A. ("Bank of America") to repurchase $50.0 million of shares of the Company's common stock, under its share repurchase program. Pursuant to the ASR Agreement,the Company paid Bank of America $50.0 million on February 19, 2026 and on that date received initial delivery of 462,535 shares, representing approximately 80% of the shares to be repurchased over the course of the ASR Agreement. On April 2, 2026, Bank of America delivered 127,070 additional shares which completed the ASR Agreement totaling 589,605 repurchased shares. The total number of shares ultimately repurchased under the ASR Agreement was based on the volume-weighted average price of the Company’s Common Stock during the repurchase period under the ASR Agreement, less a discount.
(b) Excludes excise tax due under the Inflation Reduction Act of 2022.
(c) All shares repurchase under the ASR Agreement during the quarter were made under the authorization from our Board of Directors to purchase up to $200.0 million of Integer common stock announced November 4, 2025. The share repurchase program has no expiration date and will continue until otherwise suspended or terminated.
ITEM 5.OTHER INFORMATION
Rule 10b5-1 Plan Trading Arrangements
During the fiscal quarter ended April 3, 2026, none of the Company’s directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
- 45 -

Table of Contents
ITEM 6.EXHIBITS

Exhibit Number |  | Description
10.1* |  | Fifth Amendment to Credit Agreement, dated as of March 25, 2026, among Greatbatch Ltd., Integer Holdings Corporation, the Subsidiary Guarantors party thereto, Wells Fargo Bank, National Association, as administrative agent, and the other lenders parties thereto.
10.2#* |  | Employment Offer Letter, dated April 28, 2023, for Jim Stephens.
10.3#* |  | Employment Offer Letter, dated December 16, 2024, for Lindsay Krause Blackwood.
31.1* |  | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act.
31.2* |  | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act.
32.1** |  | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS* |  | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH* |  | XBRL Extension Schema Document
101.CAL* |  | XBRL Extension Calculation Linkbase Document
101.LAB* |  | XBRL Extension Label Linkbase Document
101.PRE* |  | XBRL Extension Presentation Linkbase Document
101.DEF* |  | XBRL Extension Definition Linkbase Document
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).

* | Filed herewith.
** | Furnished herewith.
# | Indicates exhibits that are management contracts or compensation plans or arrangements.

- 46 -

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: | April 30, 2026 |  | INTEGER HOLDINGS CORPORATION
|  |  | By: |  | /s/ Payman Khales
|  |  |  |  | Payman Khales
|  |  |  |  | President and Chief Executive Officer
|  |  |  |  | (Principal Executive Officer)
|  |  | By: |  | /s/ Diron Smith
|  |  |  |  | Diron Smith
|  |  |  |  | Executive Vice President and Chief Financial Officer
|  |  |  |  | (Principal Financial Officer)
|  |  | By: |  | /s/ Tom P. Thomas
|  |  |  |  | Tom P. Thomas
|  |  |  |  | Vice President, Corporate Controller
|  |  |  |  | (Principal Accounting Officer)

- 47 -